Pergamon

Thrombosis Research 88 (1997) 527–539

THROMBOSIS RESEARCH

Author Index—Volumes 85–88 (1997)

Abate, G., see Parnetti, L. **87:**225
Abbate, R., see Chiarantini, E. **87:**539
———, see Pinto, S. **85:**185
———, see Rosati, D. **85:**273
Abdelouahed, M., I. Elalamy, M.M. Samama, M. Hatmi. Platelet aggregation by IgG anti-streptokinase and anisoylated plasminogen-streptokinase activator complex: heterogenous responses in platelet-rich plasma but not in washed platelets. **86:**255
Abdulkadir, J., Y. Feleke, J.P. Berg, J.A. Falch, O.R. Ødegaard. Absence of the factor V Leiden mutation in Ethiopians (Letter to the Editors-in-Chief). **86:**431
Adams, M.J., R. Oostryck. Further investigations of lupus anticoagulant interference in a functional assay for tissue factor pathway inhibitor. **87:**245
Adamtziki, E., see Amiral, J. **86:**73
Agraou, B., D. Corseaux, E.P. McFadden, A. Bauters, A. Cosson, B. Jude. Effects of coronary angioplasty on monocyte tissue factor response in patients with stable or unstable angina. **88:**237
Aguejouf, O., see Belougne-Malfatti, E. **88:**435
Aiach, M., see Siguret, V. **86:**85
Akai, T., see Fujii, N. **88:**299
Albert, J., see Wallén, N.H. **87:**151
Alessandri, C., see Basili, S. **85:**165
Alhenc-Gelas, M., see Siguret, V. **86:**85
Altorjay, I., see Udvardy, M. **87:**75
Amiral, J., S. Aronis, E. Adamtziki, A. Garoufi, T. Karpathios. Association of lupus anticoagulant with transient antibodies to prothrombin in a patient with hypoprothrombinemia. **86:**73
Anbo, H., see Kitaguchi, T. **87:**235
Andersen, N.T., see Hasenkam, J.M. **85:**77
Anderson, K.D., see Pendurthi, U.R. **85:**503
Andrews, R.K., see Ward, C.M. **86:**469
Antonucci, E., see Chiarantini, E. **87:**539
Aragonés, M.D., see Catalán, R.E. **87:**547
Aranda, E., see Mezzano, D. **88:**465
Arık, N., see Özdemir, O. **86:**405
Ariyoshi, H., M. Okuyama, K. Okahara, T. Kawasaki, J.-i. Kambayashi, M. Sakon, M. Monden. Expanded polytetrafluoroethylene (ePTFE) vascular graft loses its thrombogenicity six months after implantation. **88:**427
Ariyoshi, H., see Kawasaki, T. **88:**67
———, see Nakamura, T. **85:**83
Armani, U., see Leoncini, G. **86:**153
Arocha-Piñango, C.L., see Guerrero, B.A.G. **87:**83, 171
Aronis, S., see Amiral, J. **86:**73
Asada, Y., see Kisanuki, A. **85:**95
Atoda, H., E. Yoshihara, M. Yamada, T. Morita. cDNA cloning of a heterogeneous two-chain anticoagulant protein IX-bp. **87:**271
Attermann, J., see Hasenkam, J.M. **85:**77
Austin, H., W.C. Hooper, A. Dilley, C. Drews, M. Renshaw, D. Ellingsen, B. Evatt. The prevalence of two genetic traits related to venous thrombosis in whites and African-Americans. **86:**409
Aznar, J., see Vila, V. **86:**263

Bach-Gansmo, E.T., Ø. Strand, H.C. Godal, F. Wisløff, O.H. Skjønsberg. Discrepancy between latex and ELISA D-dimer values in sepsis may be caused by human neutrophil elastase. **86:**141
Baecker, C., see Weigel, G. **87:**363
Baglin, T., see Luddington, R. **87:**577
Baj, Z., see Golański, J. **85:**127
Baker, P., see Luddington, R. **87:**577
Bakhos, M., see Jeske, W.P. **88:**271
Balestreri, L., see De Cicco, M. **86:**101
Balestreri, R., see Parnetti, L. **87:**225
Bara, L., see Walenga, J.M. **86:**1
Barbanti, M., see Colucci, M. **87:**441
Barbieri, B., N. Papadogiannakis, P. Eneroth, A. Söderstedt, R. Stain-Malmgren, L.B. Olding. P-aminobenzoic acid, but not its metabolite P-acetamidobenzoic acid, inhibits thrombin induced thromboxane formation in human platelets in a non NSAID like manner. **86:**127
Barbui, T., see Norbis, F. **85:**427
Barja, P., see Mezzano, D. **88:**465
Barzu, T., see Lormeau, J.C. **85:**67
Basili, S., P. Ferroni, F.M. Pulcinelli, G. Pettirossi, M. Vieri, F. Violi, C. Alessandri, C. Cordova, P.P. Gazzaniga. Potential usefulness of antiplatelet agents in patients with chronic obstructive pulmonary disease: Correction. **85:**165
Bau, J., see Gutensohn, K. **86:**49
Bauters, A., see Agraou, B. **88:**237
Bayram, Ç., see Ulutin, T. **88:**329
Beck, K.-H., M. Kraus, J. Magsaam, V. Kretschmer, A. Leonhard, H.W. Seyberth. Prothrombin Marburg—A dysfunctional coagulation protein. **88:**337
Beck, T.C., see Østergaard, P.B. **87:**447
Beeck, H., see Hellstern, P. **86:**493
Bell, S.P., see Vinogradsky, B. **85:**305
Belloc, F., see Closse, C. **85:**159
Belougne-Malfatti, E., O. Aguejouf, F. Doutremepuich, C. Doutremepuich. Action of neurotransmitters: acetylcholine, serotonin, and adrenaline in an experimental arterial thrombosis induced by oxygen free radicals. **88:**435
Benoni, G., S. Lethagen, H. Fredin. The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. **85:**195. Correction. **88:**251
Berard, M., M.-C. Boffa. Influence of the phosphatidylethanolamine (PE) and bovine serum origins on anti-PE antibody detection by ELISA. **85:**439
Béress, L., see Dürig, J. **85:**479

0049-3848/97 $17.00 + .00 © 1998 Elsevier Science Ltd. Printed in the USA. All rights reserved.
PII S0049-3848(98)00058-9

Berg, J.P., see Abdulkadir, J. **86:**431
Bergqvist, D., see Holst, J. **86:**343
Berkels, R., K. Stockklauser, P. Rösen, R. Rösen. Current status of platelet NO synthases. **87:**51
Bernard, P., see Labrouche, S. **87:**263
Bernardi, E., see Scarano, L. **86:**93
Bernat, A., see Hoffmann, P. **86:**325
Berndt, M.C., see Ward, C.M. **86:**469
Bethge, K., see Sonntag, J. **87:**339
Beynon, J., see Grosset, A.B. **86:**349
Beythien, C., see Gutensohn, K. **86:**49
Bichler, J., see Siebeck, M. **88:**473
Björquist, P., S. Boström. Determination of the kinetic constants of tissue factor/factor VII/factor VIIa and antithrombin/heparin using surface plasmon resonance. **85:**225
Blajchman, M.A., see Cunningham, M.A. **88:**171
Blanco, E., see De La Cruz, J.P. **86:**515
Blann, A.D., C. Steele, C.N. McCollum. The influence of smoking on soluble adhesion molecules and endothelial cell markers. **85:**433
Blasevich, M., see Petroni, A. **87:**315
Blazek, I., see Leitinger, N. **86:**337
Boffa, M.-C., see Berard, M. **85:**439
Boisseau, M.R., see Closse, C. **85:**159
Bono, F., see Herbert, J.M. **86:**317
Borbolla, J.R., see Collados, M.T. **85:**465
Boström, S., see Björquist, P. **85:**225
Boswell, G.A., see Kerr, J.S. **88:**127
Botling, J., see Tenno, T. **88:**215
Boucly, C., see Raoul, M. **88:**441
Bounameaux, H., D. Didier, O. Polat, S. Desmarais, P. de Moerloose, O. Huber. Antithrombotic prophylaxis in patients undergoing laparoscopic cholecystectomy (Letter to the Editors-in-Chief). **86:**271
Bové, A., see Font, J. **86:**37
Bretschneider, E., M. Wittpoth, A.-A. Weber, E. Glusa, K. Schrör. Thrombin but not thrombin receptor activating peptide is mitogenic for coronary artery smooth muscle cells. **87:**493
Brimble, K.S., J.S. Ginsberg. Evaluation of the combination of a bedside D-dimer assay and enzyme-linked immunosorbent soluble fibrin assay in patients with suspected venous thromboembolism. **88:**291
Brito, M., see Ledford, M.R. **87:**473
Bröijersén, A., see Wallén, N.H. **87:**151
Brooks, K., see Dace, R. **87:**113
Bruhn, H.D., see Dürig, J. **85:**479
Bruhn, T., see Dürig, J. **85:**479
Bruni, V., see Pinto, S. **85:**185
Bruni, V., see Rosati, D. **85:**273
Bucciantini, S., see Rosati, D. **85:**273
Budde, U., see Zieger, B. **87:**57
Budzynski, A.Z., see Wierzbicka, I. **85:**115
Buerke, M., T. Cyrus, H. Darius. Phosphodiesterase inhibitors piroximone and enoximone inhibit platelet aggregation *in vivo* and *in vitro*. **88:**89
Bunting, R.W., R.A. Wilkinson, R.J. Callahan, H.W. Strauss, A.J. Fischman. Indium-111 DTPA-heparin: pharmacokinetics and biodistribution following subcutaneous administration in rat and rabbit. **88:**503
Burnand, K.G., see Humphries, J. **87:**123
Burrows, G.E., see Wright, D. **85:**455
Bush, L.R., see Sanchez, E.F. **87:**289
Buszko, M., see Dace, R. **87:**113
Bydlowski, S.P., see D'Amico, E.A. **85:**519
Bylund, R., see Teger-Nilsson, A.-C. **85:**133
Calanni, F., see Colucci, M. **87:**441
Callahan, R.J., see Bunting, R.W. **88:**503
Carbini, L.A., T.M. Mindroiu, S.-I. Kitamura, A.G. Scicli. Proteolytic activation of a putative receptor leading to vasoconstriction and platelet aggregation. **85:**33
Cardoso, J.L.C., see Sano-Martins, I.S. **87:**183
Carmeliet, P., see Herbert, J.M. **86:**317
Carmona, J.A., see De La Cruz, J.P. **87:**141
Carniti, G.C., see Preda, L. **86:**461
Carraro, P., see Scarano, L. **86:**93
Carroll, R.C., X.-f. Wang, F. Lanza, B. Steiner, W.C. Kouns. Blocking platelet aggregation inhibits thromboxane A_2 formation by low dose agonists but does not inhibit phosphorylation and activation of cytosolic phospholipase A_2. **88:**109
Carrubba, M., see Leoncini, G. **86:**153
Casals, F.J., see Font, J. **86:**37
Casazza, F., see Lorena, M. **87:**397
Castro, S.C.B., see Sano-Martins, I.S. **87:**183
Catalán, R.E., A.M. Martínez, M.D. Aragonés, M. Lombardía. Involvement of cyclic GMP in the mode of action of a new antithrombotic agent PCA-4230; inhibition of the platelet cyclic GMP dependent phosphodiesterase. **87:**547
Cattaneo, M., see Zighetti, M.L. **85:**279
Cellai, A.P., see Chiarantini, E. **87:**539
———, see Rosati, D. **85:**273
Cervera, R., see Font, J. **86:**37
Chabchoub, A., see Gasmi, A. **86:**233
Chamone, D.A.F., see D'Amico, E.A. **85:**519
Chan, K.-W.A., see Lee, T.-K. **87:**215
Chang, T.-W., see Lee, T.-K. **87:**215
Chen, Q., S.T. Lord, B.R. Lentz. Partially purified *Echis carinatus* venom cleaves active-site-mutated bovine prothrombin at two sites. **85:**369
Cherubini, A., see Parnetti, L. **87:**225
Chesterman, C.N., see Grimsley, P.G. **88:**485
Chetty, N., see Naran, N.H. **88:**399
Chiang, T.M. Collagen-induced platelet aggregation and release reaction: role of ras protein. **88:**205
Chiarantini, E., R. Valanzano, A.A. Liotta, A.P. Cellai, I. Ilari, D. Prisco, E. Antonucci, F. Tonelli, R. Abbate. Persistence of hemostatic alterations in patients affected by Crohn's disease after bowel surgery. **87:**539
Cho, H.-I., see Kim, Y.W. **86:**181
Christie, D.J., see Heilmann, E.J. **87:**159
Chun, H.-S., see Kim, S.-H. **87:**387
Chung, J.-H., see Chung, S.-H. **85:**345
Chung, S.-H., Kim, M.-J., Lee, J.-Y., Chung, J.-H. Effects of probenecid on platelet aggregation and cytotoxicity: drawbacks of the use of probenecid in monitoring intracellular calcium metabolism. **85:**345
Cierniewski, C.S., see Kralisz, U. **86:**287
Cimminiello, C., see Lorena, M. **87:**397
Cipolla, G.D., see Viel, K. **88:**147
Citron, B.A., I.V. Smirnova, M.N. Zoubine, B.W. Festoff. Quantitative PCR analysis reveals novel expression of prothrombin mRNA and regulation of its levels in developing mouse muscle. **87:**303
Clemens, D., see Ruzicka, K. **87:**431
Closse, C., M. Seigneur, M. Renard, A. Pruvost, P. Dumain, F. Belloc, M.R. Boisseau. Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression. **85:**159
Cole, A.T., see May, J.A. **88:**183
Collados, M.T., J. Fernández, J.A. Páramo, R. Montes, J.R. Borbolla, L.F. Montaño, E. Rocha. Purification and characteriza-

tion of a variant of human prothrombin: prothrombin Segovia. **85:**465
Collet, C., see Raoul, M. **88:**441
Colucci, M., L. Sardella, M. Barbanti, F. Calanni, N. Semeraro. Thrombolysis enhancing activity of a low molecular weight dermatan sulfate (Desmin 370) in experimental pulmonary embolism in rats. **87:**441
Coppola, R., see Parnetti, L. **87:**225
Cordova, C., see Basili, S. **85:**165
Cornillet, P., see Hézard, N. **88:**59
Corseaux, D., see Agraou, B. **88:**237
Cosson, A., see Agraou, B. **88:**237
Costanzo, M., see Pinto, S. **85:**185
Crawford, V.L.S., see McNerlan, S.E. **88:**481
Cucinotta, D., see Parnetti, L. **87:**225
Cui, J., see Viel, K. **88:**147
Cullinane, A., see Merryman, P. **86:**525
Cunningham, M.A., M.A. Blajchman, W.P. Sheffield. Impact of mutations at the P4 and P5 positions on the reaction of antithrombin with thrombin and elastase. **88:**171
Cyrus, T., see Buerke, M. **88:**89

Dace, R., E. McBride, K. Brooks, J. Gander, M. Buszko, V.M. Doctor. Comparison of the anticoagulant action of sulfated and phosphorylated polysaccharides. **87:**113
Dahlbäck, B., see Zöller, B. **85:**237
Dameron, C.T., see Liu, L. **85:**399
D'Amico, E.A., D.A.F. Chamone, S.P. Bydlowski. In vitro effects of rt-PA on platelet function and clot strength. **85:**519
Dardik, R., see Varon, D. **85:**283
Darius, H., see Buerke, M. **88:**89
Dau, O., see Lins, M. **86:**433
De Cicco, M., M. Matovic, L. Balestreri, G. Panarello, D. Fantin, S. Morassut, V. Testa. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. **86:**101
De La Cruz, J.P., M. Martín-Romero, J.A. Carmona, M.A. Villalobos, F. Sánchez de la Cuesta. Effect of evening primrose oil on platelet aggregation in rabbits fed an atherogenic diet. **87:**141
De La Cruz, J.P., M.A. Maximo, E. Blanco, A. Moreno, F. Sánchez de la Cuesta. Effect of erythrocytes and prostacyclin production in the effect of fructose and sorbitol on platelet activation in human whole blood *in vitro*. **86:**515
Delgado, L., see Ledford, M.R. **87:**473
Dell'Acqua, G., L. Iacoviello, A. D'Orazio, A. Di Castelnuovo, M.B. Donati. A polymorphic cluster in the 5′ region of the human coagulation factor VII gene: detection, frequency, and linkage disequilibrium. **88:**445
Dellagi, K., see Gasmi, A. **86:**233
———, see Guermazi, S. **86:**197
de Mazancourt, P., see Raoul, M. **88:**441
de Moerloose, P., see Bounameaux, H. **86:**271
Deng, J.-C., see Lee, T.-K. **87:**215
Desmarais, S., see Bounameaux, H. **86:**271
Despotis, G.J., S. Ikonomakou, V. Levine, D. Joiner-Maier, S.A. Santoro, J.H. Joist. Effects of platelets and white blood cells and antiplatelet agent c7E3 (Reopro™) on a new test of PAF procoagulant activity of whole blood. **86:**205
Devynck, M.-A., see Kuneš, J. **88:**347
Di Braccio, M., see Leoncini, G. **87:**483
Di Castelnuovo, A., see Dell'Acqua, G. **88:**445
Didier, D., see Bounameaux, H. **86:**271
Dikshit, M., see Seth, P. **87:**279
Dilley, A., see Austin, H. **86:**409
Doctor, V.M., see Dace, R. **87:**113
———, see Minix, R. **87:**419
Domagala, T.B., M. Libura, A. Szczeklik. Hyperhomocysteinemia following oral methionine load is associated with increased lipid peroxidation. **87:**411
Donati, M.B., see Dell'Acqua, G. **88:**445
D'Orazio, A., see Dell'Acqua, G. **88:**445
Doutremepuich, C., see Belougne-Malfatti, E. **88:**435
Doutremepuich, F., see Belougne-Malfatti, E. **88:**435
Downey, P., see Mezzano, D. **88:**465
Drews, C., see Austin, H. **86:**409
Drohan, W., see Kaiser, B. **87:**197
Droullé, C., see Hézard, N. **88:**59
Druzhyna, N.N., E.M. Makogonenko, S.A. Yakovlev. Studies of the t-PA-catalyzed Glu-plasminogen activation on different models of polymeric fibrin. **87:**131
Duboscq, C., V. Genoud, M.F. Parborell, L.C. Kordich. Impaired clot lysis by rt-PA catalyzed mini-plasminogen activation. **86:**505
Dudenhausen, J.W., see Sonntag, J. **87:**339
Dumain, P., see Closse, C. **85:**159
Dumas, A., see Hoffmann, P. **86:**325
Dündar, S., see Özdemir, O. **86:**405
Dürig, J., T. Bruhn, K.-H. Zurborn, K. Gutensohn, H. D. Bruhn, L. Béress. Anticoagulant fucoidan fractions from *Fucus vesiculosus* induce platelet activation in vitro. **85:**479
Dyerberg, J., see Møller, J.M. **86:**333

Efthimiou, Y., see Pirich, C. **88:**41
Eichinger, S., see Ruzicka, K. **87:**431
Ekelund, S., see Møller, J.M. **86:**333
Elalamy, I., see Abdelouahed, M. **86:**255
Elayeb, M., see Gasmi, A. **86:**233
Ellingsen, D., see Austin, H. **86:**409
El-Sabban, F., G.M.H. Radwan. Influence of garlic compared to aspirin on induced photothrombosis in mouse pial microvessels, *in vivo*. **88:**193
Emm, T.A., see Kapil, R.P. **86:**221
Endo, A., see Tachikawa, K. **87:**571
Eneroth, P., see Barbieri, B. **86:**127
Erba, N., see Preda, L. **86:**461
Eriksson, U., see Teger-Nilsson, A.-C. **85:**133
Ero, M., see Jeske, W.P. **88:**271
Escolar, G., see Serra, A. **87:**405
Esteve, J., see Serra, A. **87:**405
Evatt, B., see Austin, H. **86:**409
Ezban, M., see Hansen, J.-B. **85:**413

Facchinetti, F., see Marietta, M. **88:**229
Falch, J.A., see Abdulkadir, J. **86:**431
Falcon, C.R., see Zighetti, M.L. **85:**279
Faller-Stöckl, B., see Hellstern, P. **86:**493
Fan, H.W., see Sano-Martins, I.S. **87:**183
Fantin, D., see De Cicco, M. **86:**101
Fareed, J., see Fu, K. **86:**355
———, see Hoppensteadt, D.A. **88:**159
———, see Kaiser, B. **87:**197
———, J., see Walenga, J.M. **86:**1
———, see Yang, L.H. **86:**479
Farías, C.E., J.C. Giménez, A.C. Kempfer, E. Singer, A.I. Woods, M.T. Santarelli, M.A. Lazzari. Ionizing radiation increases concentration of plasma von Willebrand factor in *Cebus Apella Paraguayanus* monkeys. **88:**81
Farrell, D.H., see Wierzbicka, I. **85:**115
Farzame, N., see Varon, D. **85:**283

Fedi, S., see Rosati, D. **85:**273
Feleke, Y., see Abdulkadir, J. **86:**431
Fellhauer, A., see Hellstern, P. **86:**493
Fernández, J., see Collados, M.T. **85:**465
Ferrari, P., see Parnetti, L. **87:**225
Ferro, L., see Fisher, J. **85:**445
Ferroni, P., see Basili, S. **85:**165
Fersini, C., see Manfredini, R. **88:**451
Festoff, B.W., see Citron, B.A. **87:**303
Fiessinger, J.N., see Siguret, V. **86:**85
Figini, S., see Preda, L. **86:**461
Finkelberg, L., see Pennewitz, A. **86:**427
Fischer, A., see Hellstern, P. **86:**493
Fischman, A.J., see Bunting, R.W. **88:**503
Fisher, J., T.K. Holland, R. Pescador, R. Porta, L. Ferro. Pharmacokinetics, absorption, distribution and disposition of [^{125}I]-oligotide following intravenous or oral administration in the rat. **85:**445
Fitscha, P., see Kritz, H. **87:**257
Font, J., A. López-Soto, R. Cervera, F.J. Casals, J.C. Reverter, F.J. Muñoz, C. Miret, A. Bové, A. Ordinas, M. Ingelmo. Antibodies to thromboplastin in systemic lupus erythematosus: isotype distribution and clinical significance in a series of 92 patients. **86:**37
Forsythe, M.S., see Tsao, P.W. **88:**137
Fredin, H., see Benoni, G. **85:**195
Freese, R., M. Mutanen. Small effects of linseed oil or fish oil supplementation on postprandial changes in hemostatic factors. **85:**147
Freyburger, G., see Labrouche, S. **87:**263
Fu, K., R. Izquierdo, D. Vandevender, R.L. Warpeha, H. Wolf, J. Fareed. Topical application of low molecular weight heparin in a rabbit traumatic anastomosis model. **86:**355
Fu, K., see Hoppensteadt, D.A. **88:**159
Fujii, K., see Suzuki, S. **88:**499
Fujii, N., T. Kaji, T. Akai, F. Koizumi. Thrombin reduces large heparan sulfate proteoglycan molecules in cultured vascular endothelial cell layers through inhibition of core protein synthesis. **88:**299
Fujii, S., see Vinogradsky, B. **85:**305
Fujishima, M., see Yoshinari, M. **86:**443
Fujiwara, K., see Yamanobe, F. **85:**493
Fujiyoshi, T., see Katada, J. **88:**27
Funahara, Y., see Kisanuki, A. **85:**95
Funayama, H., Y. Sakata, S.-I. Kitagawa, U. Ikeda, M. Takahashi, J.-I. Masuyama, J. Mimuro, M. Matsuda, K. Shimada. Monocytes modulate the fibrinolytic balance of endothelial cells. **85:**377

Gabaldón, M., see Zúñiga, A. **86:**243
Gabbeta, J., see Yang, X. **88:**317
Gable, P.S., D.T. Le, S.I. Rapaport. Protac, a commercially available protein C activator from the venom of *Agkistrodon contortrix contortrix*, can activate factor V and factor VIII. **86:**79
Gaffney, P.J., see Humphries, J. **87:**123
Gaich, C., see Lormeau, J.C. **85:**67
Galajda, P., E. Martinka, M. Mokáň, P. Kubisz. Endothelial markers in diabetes mellitus. **85:**63
Gallerani, M., see Manfredini, R. **88:**451
Galli, C., see Petroni, A. **87:**315
Galli, M., see Norbis, F. **85:**427
Gallistl, S., W. Muntean, B. Leschnik, W. Meyers. Longer aPTT values in healthy children than in adults: no single cause. **88:**355
Gander, J., see Dace, R. **87:**113
Garcia, C., see Heilmann, E.J. **87:**159
Garoufi, A., see Amiral, J. **86:**73
Gasmi, A., A. Chabchoub, S. Guermazi, H. Karoui, M. Elayeb, K. Dellagi. Further characterization and thrombolytic activity in a rat model of a fibrinogenase from *Vipera lebetina* venom. **86:**233
Gaussem, P., see Siguret, V. **86:**85
Gazzaniga, P.P., see Basili, S. **85:**165
———, see Pulcinelli, F.M. **85:**207
Genoud, V., see Duboscq, C. **86:**505
Gialeraki, A., see Makris, T.K. **88:**99
Giddings, J.C., see Kawano, M. **86:**115
———, see Yamashita, T. **85:**45
Gillot, L., see Hézard, N. **88:**59
Giménez, J.C., see Farías, C.E. **88:**81
Ginsberg, J.S., see Brimble, K.S. **88:**291
Gippner-Steppert, C., see Siebeck, M. **88:**473
Girolami, A., see Scarano, L. **86:**93
Giusti, B., see Pinto, S. **85:**185
Glusa, E., see Bretschneider, E. **87:**493
Godal, H.C., see Bach-Gansmo, E.T. **86:**141
Gökmen, O., see Haznedaroğlu, Ş. **86:**89
Golański, J., T. Pietrucha, Z. Baj, J. Greger, C. Watala. A novel approach to inhibit the anticoagulant-induced spontaneous activation of blood platelets—effect of magnesium on platelet release reaction in whole blood. **85:**127
Gomez, R., see Heilmann, E.J. **87:**159
González, F., see Mezzano, D. **88:**465
Gordon, S.G., see Mielicki, W.P. **87:**251
Goto, Y., see Muramatsu, R. **86:**453
Gouault-Heilmann, M., C. Leroy-Matheron. Evaluation of a new chronometric assay for factor V Leiden-dependent APC resistance. **85:**357
Govers-Riemslag, J.W.P., see Petrovan, R.J. **88:**309
Graf, S., see Watzke, H.H. **87:**521
Gralnick, H.R., see Krutzsch, H. **88:**333
———, see Williams, S.B. **86:**417
Graver, V., A.K. Haaland, M. Loeb, A.E. Ljunggren. Fibrinolytical activity in relation to psychological traits in patients with sciatica. **85:**363
Greger, J., see Golański, J. **85:**127
Griesmacher, A., see Weigel, G. **87:**363
Grimsley, P.G., K.A. Quinn, C.N. Chesterman, D.A. Owensby. Low density lipoprotein receptor-related protein (LRP) expression varies among Hep G2 Cell Lines. **88:**485
Grønnesby, H., see Hasenkam, J.M. **85:**77
Grosset, A.B., T.E. Spiro, J. Beynon, G.M. Rodgers. Enoxaparin, a low-molecular weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism. **86:**349
Grossi, G.C., see Leoncini, G. **87:**483
Guermazi, S., M. Hamza, K. Dellagi. Protein S deficiency and antibodies to protein S in patients with Behcet's disease. **86:**197
Guermazi, S., see Gasmi, A. **86:**233
Guerrero, B.A.G., C.L. Arocha-Piñango, A.G. San Juan. Lonomia achelous caterpillar venom (LACV) selectively inactivates blood clotting factor XIII. **87:**83
———. Degradation of human factor XIII by Lonomin V, a purified fraction of *Lonomia achelous* caterpillar venom. **87:**171
Günzler, W.A., see Wnendt, S. **85:**217
Gupta, J.B., see Ray, A. **87:**37
Gurbel, P.A., V.L. Serebruany. Myths and realities of P-selectin plasma levels in patients with acute myocardial infarction (Letter to the Editors-in-Chief). **88:**343
Gustafsson, D., see Teger-Nilsson, A.-C. **85:**133
Gutensohn, K., C. Beythien, J. Bau, T. Meinertz, P. Kuehnl. Flow

cytometric analysis of coronary stent-induced alterations of platelet antigens in an *in vitro* model. **86:**49
Gutensohn, K., see Dürig, J. **85:**479
Gyzander, E., see Teger-Nilsson, A.-C. **85:**133

Haaland, A.K., see Graver, V. **85:**363
Haas, S., see Jeske, W.P. **88:**271
Haga, S., see Ikarugi, H. **85:**351
Hamers, M.J.A.G., see Örning, L. **86:**57
Hamza, M., see Guermazi, S. **86:**197
Han, M.H., see Kim, S.-H. **87:**387
Handler, S., see Ruzicka, K. **87:**431, 501
Handley, D.A., T.E. Hughes. Pharmacological approaches and strategies for therapeutic modulation of fibrinogen. **87:**1
Hansen, J.-B., K.R. Huseby, N.-E. Huseby, M. Ezban, A. Nordøy. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. **85:**413
Hansen, J.-B., see Østergaard, P.B. **87:**447
Harari, S., see Zighetti, M.L. **85:**279
Harlow, P.P., see Kerr, J.S. **88:**127
———, see Zhang, Z.-Y. **88:**389
Harsfalvi, J., see Udvardy, M. **87:**75
Hartmann, M., see van Zyl, W.B. **88:**419
Hasenkam, J.M., L. Knudsen, H.H. Kimose, H. Grønnesby, J. Attermann, N.T. Andersen, H.K. Pilegaard. Practicability of patient self-testing of oral anticoagulant therapy by the international normalized ratio (INR) using a portable whole blood monitor. A pilot investigation. **85:**77
Hashimoto, N., see Hashimoto, Y. **88:**51
Hashimoto, Y., M. Togo, H. Sato, N. Hashimoto, T. Watanabe, K. Kurokawa, K. Nakahara. Characteristics of protein kinase C-independent exocytosis in human platelets. **88:**51
Hasumi, K., see Tachikawa, K. **87:**571
Hatmi, M., see Abdelouahed, M. **86:**255
Hatzizacharias, A., see Makris, T.K. **88:**99
Haugen, G., see Schjetlein, R. **85:**153
Hawkey, C.J., see May, J.A. **88:**183
Hayakawa, Y., see Hayashi, T. **87:**105
Hayashi, H., see Komatsu, Y. **87:**343
———, see Muramatsu, R. **86:**453
Hayashi, T., Y. Hayakawa, T. Hayashi, H. Sasaki, N. Sakuragawa. Sulfated polysaccharide from the leaves of *Artemisia princeps* activates heparin cofactor II independently of the Lys^{173} and Arg^{189} residues of heparin cofactor II. **87:**105
Hayashi, T., see Hayashi, T. **87:**105
Haznedaroğlu, İ., see Özdemir, O. **86:**405
Haznedaroğlu, İ.C., see Haznedaroğlu, Ş. **86:**89
Haznedaroğlu, Ş., T. Özcan, S. Malkoç, O. Gökmen, İ.C. Haznedaroğlu, Ş. Kirazlı. Hemostatic markers in preterm labor (Letter to the Editors-in-Chief). **86:**89
Head, D.M., I.T.W. Matthews, M.A. Tones. Effect of divalent metal ions on the binding of tissue factor and activated factor VII. **85:**327
Hedner, U., see Holst, J. **86:**343
Hegde, L.G., see Ray, A. **87:**37
Heilmann, E.J., S.K. Kundu, R. Sio, C. Garcia, R. Gomez, D.J. Christie. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100™ system. **87:**159
Heinrich, F., see Knecht, M.F. **88:**413
Heinzl, H., see Weigel, G. **87:**363
Hellstern, P., H. Beeck, A. Fellhauer, A. Fischer, B. Faller-Stöckl. Measurement of factor VII and of activated factor VII in healthy individuals and in prothrombin complex concentrates. **86:**493
Hemker, H.C., see Petrovan, R.J. **88:**309
Henrikson, K.P., S.M. Quirk, A. Restivo. Expression of rat thrombin receptor and mutants in the baculovirus-infected insect cell system. **87:**205
Heptinstall, S., see May, J.A. **88:**183
Hérault, J.P., see Hoffmann, P. **86:**325
Herault, J.P., see Lormeau, J.C. **85:**67
Herbert, J.M., F. Bono, I. Lamarche, P. Carmeliet. The inhibitory effect of heparin for vascular smooth muscle cell proliferation or migration is not mediated by u-PA and t-PA. **86:**317
Herbert, J.M., see Hoffmann, P. **86:**325
———, see Hoppensteadt, D.A. **88:**159
———, see Jeske, W.P. **88:**271
———, see Lormeau, J.C. **85:**67
Herrmann, G., see Lins, M. **86:**433
Hézard, N., P. Cornillet, C. Droullé, L. Gillot, G. Potron, P. Nguyen. Factor V Leiden: detection in whole blood by ASA PCR using an additional mismatch in antepenultimate position. **88:**59
Hillarp, A., see Zöller, B. **85:**237
Hirst, C.F., see Wright, D. **85:**455
Hladovec, J., Z. Sommerová, A. Písaříková. Homocysteinemia and endothelial damage after methionine load. **88:**361
Ho, C.-H. Prevalence of activated protein C resistance in the Chinese population. **88:**409
Hoffmann, H., see Siebeck, M. **88:**473
Hoffmann, P., A. Bernat, A. Dumas, M. Petitou, J.P. Hérault, J.M. Herbert. The synthetic pentasaccharide SR 90107A/Org 31540 does not release lipase activity into the plasma. **86:**325
Holland, T.K., see Fisher, J. **85:**445
Holst, J., B. Lindblad, D. Bergqvist, U. Hedner, O. Nordfang, P. Østergaard. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular-weight heparin in man. **86:**343
Hooper, W.C., see Austin, H. **86:**409
Hoppensteadt, D.A., W.P. Jeske, J.M. Walenga, K. Fu, L.H. Yang, T. Ing, J.M. Herbert, J. Fareed. Efficacy of pentasaccharide in a dog model of hemodialysis. **88:**159
Hoppensteadt, D.H., see Kaiser, B. **87:**197
Horie, S., see Oida, K. **85:**169
Horne, M. III, see Merryman, P. **86:**525
Hornykewycz, S., see Ruzicka, K. **87:**431
Horton, A., see Ledford, M.R. **87:**473
Hsieh, K.-h. Thrombin interaction with fibrin polymerization sites. **86:**301
Hu, H.-H., see Lee, T.-K. **87:**215
Huang, Z.-S., see Lee, T.-K. **87:**215
Huber, K., see Ruzicka, K. **87:**431
———, see Watzke, H.H. **87:**521
Huber, O., see Bounameaux, H. **86:**271
Hughes, T.E., see Handley, D.A. **87:**1
Humphries, J., C. Lattimer, A. Smith, C.L. McGuinness, C. Whitton, P.J. Gaffney, K.G. Burnand. High and constant plasma levels of tissue plasminogen activator and PEG-hirudin can be achieved by subcutaneous delivery. **87:**123
Hund, S., see Pötzsch, B. **86:**373
Hung, W.-C., see Sheu, J.-R. **88:**259
Huseby, K.R., see Hansen, J.-B. **85:**413
Huseby, N.-E., see Hansen, J.-B. **85:**413
Huszka, M., M. Kaplar, L. Rejto, I. Tornai, K. Palatka, P. Laszlo, M. Udvardy. The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and

increased in vivo platelet activation in patients with diabetes mellitus. **86:**173

Iacoviello, L., see Dell'Acqua, G. **88:**445
Ichinose, A., see Saito, T. **87:**527
Iguchi, K., S. Murakami, A. Matsumoto, A. Shimizu, N. Sakuragawa. Abnormally high level of antithrombin in a case with hepatocellular carcinoma: Correction. **85:**167
Ikarugi, H., T. Taka, S. Nakajima, N. Kato, T. Ueda, K. Matsumura, S. Haga, J. Yamamoto. Detection of a prothrombotic state after acute aerobic exercise. **85:**351
Ikeda, M., see Nakamura, T. **85:**83
Ikeda, U., see Funayama, H. **85:**377
Ikeda, Y., see Kitaguchi, T. **87:**235
Ikonomakou, S., see Despotis, G.J. **86:**205
Ilari, I., see Chiarantini, E. **87:**539
Imiya, M., T. Matsuo. Inhibition of collagen-induced platelet aggregation by argatroban in patients with acute cerebral infarction. **88:**245
Ing, T., see Hoppensteadt, D.A. **88:**159
Ingelmo, M., see Font, J. **86:**37
Inoue, N., see Ozawa, T. **85:**515
Iomhair, M.M., S.M. Lavelle. Quantitation of the thrombotic effects in artery and vein of the increase in coagulation factors during normal pregnancy in the rat. **87:**359
Iomhair, M.M., see Lavelle, S.M. **87:**353
Ishii, H., see Oida, K. **85:**169
Ishikawa, K., see Yamanobe, F. **85:**493
Iwase, M., see Yoshinari, M. **86:**443
Izquierdo, R., see Fu, K. **86:**355

Jacobsen, E.M., F. Wisløff. A simple procedure that increases the specificity of the activated protein C resistance test in samples containing antiphospholipid antibodies. **86:**385
James, H.L., see Pendurthi, U.R. **85:**503
Janin, A., see Mabilat-Pragnon, C. **88:**373
Janssen, M.C.H., B.W. Verbruggen, P.J.C. ter Hark, I.R.O. Nováková. Factor VIIa determination compared to D-dimer in diagnosis of deep venous thrombosis. **86:**423
Jaouen, E., see Raoul, M. **88:**441
Javorschi, S., see Labrouche, S. **87:**263
Jerling, J.C., see Veldman, F.J. **86:**183
Jeske, W., see Kaiser, B. **87:**197
Jeske, W.P., J.M. Walenga, E. Szatkowski, M. Ero, J.M. Herbert, S. Haas, M. Bakhos. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. **88:**271
Jeske, W.P., see Hoppensteadt, D.A. **88:**159
———, see Walenga, J.M. **86:**1
Jessat, U., see Zieger, B. **87:**57
Jilma, B., see Novacek, G. **88:**283
———, see Ruzicka, K. **87:**431, 501
Jochum, M., see Siebeck, M. **88:**473
Joiner-Maier, D., see Despotis, G.J. **86:**205
Joist, J.H., see Despotis, G.J. **86:**205
Jude, B., see Agraou, B. **88:**237
Juji, T., see Shiba, M. **87:**511

Kaiser, B., W. Jeske, D.H. Hoppensteadt, J.M. Walenga, W. Drohan, J. Fareed. In vitro studies on the effect of activated protein C on platelet activation and thrombin generation. **87:**197
Kaji, T., see Fujii, N. **88:**299
Kaliman, J., see Kritz, H. **87:**257
Kambayashi, J.-i., see Ariyoshi, H. **88:**427
———, see Kawasaki, T. **88:**67
———, see Nakamura, T. **85:**83
Kaminsky, L.S., see Zhang, Z.-Y. **88:**389
Kan, Y.-C., see Sheu, J.-R. **88:**259
Kapil, R.P., T.A. Emm, S.A. Mousa, P.K. Padovani, C.Y. Quon, G.N. Lam. Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIb/IIa receptor antagonist, XU063, in beagle dogs. **86:**221
Kapiotis, S., see Novacek, G. **88:**283
———, see Ruzicka, K. **87:**431, 501
Kaplar, M., see Huszka, M. **86:**173
Kariyazono, H., see Nakamura, K. **86:**161
Karoui, H., see Gasmi, A. **86:**233
Karpathios, T., see Amiral, J. **86:**73
Katada, J., Y. Takiguchi, M. Muramatsu, T. Fujiyoshi, I. Uno. The *in vitro* and *in vivo* pharmacological profiles of a platelet glycoprotein IIb/IIIa antagonist, NSL-9403. **88:**27
Kato, N., see Ikarugi, H. **85:**351
Kätzel, R., see Zieger, B. **87:**57
Kawahara, N., see Ozawa, T. **85:**515
Kawamura, M., N. Tsuji, N. Moriya, Z.-i. Terashita. Effects of -TAK-029, a novel GPIIb/IIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys. **86:**275
Kawano, M., S. Watanabe, Y. Sasaki, J.C. Giddings, J. Yamamoto. Adjuvant effect of argatroban on staphylokinase induced thrombolysis of platelet rich thrombi in rat mesenteric venules *in vivo*. **86:**115
Kawasaki, T., J.-i. Kambayashi, H. Ariyoshi, M. Sakon, E. Suehisa, M. Monden. Hypercholesterolemia as a risk factor for deep-vein thrombosis. **88:**67
Kawasaki, T., see Ariyoshi, H. **88:**427
———, see Nakamura, T. **85:**83
Kempfer, A.C., see Farías, C.E. **88:**81
Kerr, J., see Zhang, Z.-Y. **88:**389
Kerr, J.S., H.-Y. Li, R.S. Wexler, A.J. Robinson, C.S. Robinson, G.A. Boswell, C. Krauthauser, P.P. Harlow. The characterization of potent novel warfarin analogs. **88:**127
Kęsy, A., see Walkowiak, B. **87:**95
Kietthubthew, S., see Kisanuki, A. **85:**95
Kim, M.-J., see Chung, S.-H. **85:**345
Kim, S.-H., H.-S. Chun, M.H. Han, N.-Y. Park, K. Suk. A novel variant of staphylokinase gene from *Staphylococcus aureus* ATCC 29213. **87:**387
Kim, S.-H., J.-Y. Lee, W.-Y. Lee, K. Suk. Sphingosine stimulates thrombin-induced gelation of the fibrinogen. **87:**331
Kim, Y.W., K.-Y. Yoon, S. Park, Y.-S. Shim, H.-I. Cho, S.S. Park. Absence of factor V Leiden mutation in Koreans (Letter to the Editors-in-Chief). **86:**181
Kimose, H.H., see Hasenkam, J.M. **85:**77
King, S.B., III, see Viel, K. **88:**147
Kirazlı, Ş., see Haznedaroğlu, Ş. **86:**89
Kisanuki, A., S. Kietthubthew, Y. Asada, K. Marutsuka, Y. Funahara, A. Sumiyoshi. Intravenous injection of sonicated blood induces pulmonary microthromboembolism in rabbits with ligation of the splenic artery. **85:**95
Kishi, Y., see Sakita, S.-y. **87:**461
Kitagawa, S.-I., see Funayama, H. **85:**377
Kitaguchi, T., M. Murata, H. Anbo, T. Moriki, Y. Ikeda. Characterization of the gene encoding mouse platelet glycoprotein Ibβ[1]. **87:**235
Kitamura, S.-I., see Carbini, L.A. **85:**33
Klinge, J., see Ries, M. **85:**341
Knecht, M.F., F. Heinrich. Clinical evaluation of an immunoturbidimetric D-dimer assay in the diagnostic procedure of deep vein thrombosis and pulmonary embolism. **88:**413
Knudsen, L., see Hasenkam, J.M. **85:**77

Ko, W.-C., see Sheu, J.-R. **88:**259
Kogan, A.E., see Umarova, B.A. **85:**267
Kohno, M., see Oida, K. **85:**169
Koide, M., see Suzuki, S. **88:**499
Koizumi, F., see Fujii, N. **88:**299
Kökoğlu, E., see Ulutin, T. **88:**329
Komatsu, Y., H. Hayashi. Reevaluating the effects of tyrosine iodination of recombinant hirudin on its thrombin inhibition kinetics. **87:**343
Kordich, L.C., see Duboscq, C. **86:**505
Kotev-Emeth, S., see Varon, D. **85:**283
Kotzé, H.F., see van Zyl, W.B. **88:**419
Kouns, W.C., see Carroll, R.C. **88:**109
Kowalska, M.A., see Wierzbicka, I. **85:**115
Kralisz, U., C.S. Cierniewski. Differential effects of the tyrosine kinase inhibitors on collagen type 1-induced platelet aggregation and adhesion to this protein. **86:**287
Kraus, M., see Beck, K.-H. **88:**337
Krause, S., see Pennewitz, A. **86:**427
Krauthauser, C., see Kerr, J.S. **88:**127
Krespi, P., see Makris, T.K. **88:**99
Kretschmer, V., see Beck, K.-H. **88:**337
Kritz, H., A. Oguogho, P. Fitscha, J. Kaliman, W. Rogatti, H. Sinzinger. Platelet response during prostaglandin E_1-therapy in patients with non-insulin-dependent diabetes mellitus. **87:**257
Kritz, H., see O'Grady, J. **86:**363
Krutzsch, H., S.B. Williams, L.P. McKeown, H.R. Gralnick. Structure-function studies on the inhibition of binding of α-thrombin to platelet GpIbα by the peptide D-Y-Y-P-E and the artifactual inhibitory activity of C-terminal E in this peptide. **88:**333
Krutzsch, H., see Williams, S.B. **86:**417
Kubisz, P., see Galajda, P. **85:**63
Kudo, T., see Ozawa, T. **85:**515
Kuehnl, P., see Gutensohn, K. **86:**49
Kumari, R., see Seth, P. **87:**279
Kundu, S.K., see Heilmann, E.J. **87:**159
Kuneš, J., M.M. Mazeaud, M.-A. Devynck, J. Zicha. Platelet hypoaggregability in hereditary hypertriglyceridemic rats: relation to plasma triglycerides. **88:**347
Kuriyama, M., see Saito, T. **87:**527
Kurokawa, K., see Hashimoto, Y. **88:**51
Kvernmo, H.D., B. Østerud. The effect of physical conditioning suggests adaptation in procoagulant and fibrinolytic potential. **87:**559. Correction. **88:**253

Labrouche, S., S. Javorschi, P. Bernard, G. Freyburger. Molecular mechanism for APC resistance in the absence of Arg 506 mutation: factor V gene sequencing strategy. **87:**263
Ladjevardi, M., see Wallén, N.H. **87:**151
Lai, M.-L., see Lee, T.-K. **87:**215
Laibelman, A.M., see Lin, P.H. **88:**365
Lam, G.N., see Kapil, R.P. **86:**221
Lamarche, I., see Herbert, J.M. **86:**317
Lanza, F., see Carroll, R.C. **88:**109
Lasz, E.C., see Wierzbicka, I. **85:**115
Laszlo, P., see Huszka, M. **86:**173
Lattimer, C., see Humphries, J. **87:**123
Lavelle, S.M., M.M. Iomhair. The reliability of thrombotic tendency measured by intravascular wires in the rat. **87:**353
Lavelle, S.M., see Iomhair, M.M. **87:**359
Lazzari, M.A., see Farías, C.E. **88:**81
Le, D.T., see Gable, P.S. **86:**79
Ledford, M.R., A. Horton, G. Wang, M. Brito, L. Delgado. Efficacy of danazol in a patient with congenital protein S deficiency: paradoxical evidence for decreased platelet activation with increased thrombin generation. **87:**473
Lee, J.-Y., see Chung, S.-H. **85:**345
———, see Kim, S.-H. **87:**331
Lee, K.-Y., see Lee, T.-K. **87:**215
Lee, T.-K., K.-W.A. Chan, Z.-S. Huang, S.-K. Ng, R.-T. Lin, H.L. Po, R.-Y. Yuan, M.-L. Lai, T.-W. Chang, S.-H. Yan, J.-C. Deng, L.-H. Liu, K.-Y. Lee, S.-K. Lie, S.-M. Sung, H.-H. Hu. Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the ASA Study Group in Taiwan. **87:**215
Lee, W.-Y., see Kim, S.-H. **87:**331
Legrand, Y., see Mabilat-Pragnon, C. **88:**373
Leitinger, N., I. Blazek, H. Sinzinger. The influence of isoprostanes on ADP-induced platelet aggregation and cyclic AMP-generation in human platelets. **86:**337
Lentz, B.R., see Chen, Q. **85:**369
Leoncini, G., M.G. Signorello, G.C. Grossi, M. Di Braccio. Mechanism of action of two new pyrimidoquinoline and isoquinoline derivatives in human platelets. **87:**483
Leoncini, G., M.G. Signorello, A. Piana, M. Carrubba, U. Armani. Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. **86:**153
Leonhard, A., see Beck, K.-H. **88:**337
Leroy-Matheron, C., see Gouault-Heilmann, M. **85:**357
Leschnik, B., see Gallistl, S. **88:**355
Lethagen, S., see Benoni, G. **85:**195
Levine, V., see Despotis, G.J. **86:**205
Lewandowski, K., M. Rożek, K. Zawilska, W.T. Markiewicz. An alternative method for identifying the factor V gene Leiden mutation. **85:**105
Li, H.-Y., see Kerr, J.S. **88:**127
———, see Zhang, Z.-Y. **88:**389
Li, J.-Z., see Peng, L. **87:**65
Libura, M., see Domagala, T.B. **87:**411
Lie, S.-K., see Lee, T.-K. **87:**215
Lin, J.-S., see Shen, M.-C. **87:**377
Lin, P.H., A.M. Laibelman, U. Sinha. Reversible acylation of factor Xa as a potential therapy for hemophilia. **88:**365
Lin, R.-T., see Lee, T.-K. **87:**215
Lindblad, B., see Holst, J. **86:**343
Lins, M., K.-H. Zurborn, O. Dau, E. Nagel, S. Muurling, G. Herrmann, R. Simon. Coagulation activation in patients undergoing directional coronary atherectomy. **86:**433
Liotta, A.A., see Chiarantini, E. **87:**539
———, see Rosati, D. **85:**273
Liu, L., D.K. Murray, C.T. Dameron, C.J. Parker, G.M. Rodgers. Biochemical characterization of procoagulant albumin. **85:**399
Liu, L.-H., see Lee, T.-K. **87:**215
Ljunggren, A.E., see Graver, V. **85:**363
Lockwood, C.J., see Zangari, M. **85:**177
Loeb, M., see Graver, V. **85:**363
Lombardi, R., see Zighetti, M.L. **85:**279
Lombardía, M., see Catalán, R.E. **87:**547
López-Soto, A., see Font, J. **86:**37
Lord, S.T., see Chen, Q. **85:**369
Lorena, M., S. Perolini, F. Casazza, M. Milani, C. Cimminiello. Fluvastatin and tissue factor pathway inhibitor in type IIA and IIB hyperlipidemia and in acute myocardial infarction. **87:**397
Lormeau, J.C., J.P. Herault, C. Gaich, T. Barzu, T.G. van Dinther, A. Visser, J.M. Herbert. Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107A/Org 31540 and of two structural analogues. **85:**67
Lösche, W., see Pennewitz, A. **86:**427
Lozano, M., see Serra, A. **87:**405
Lu, H., see Mabilat-Pragnon, C. **88:**373

Lucena-Solano, O., see Pèrez-Requejo, J.L. **85:**259
Luddington, R., J. Peters, P. Baker, T. Baglin. The effect of delayed analysis or freeze-thawing on the measurement of natural anticoagulants, resistance to activated protein C and markers of activation of the haemostatic system. **87:**577

Mabilat-Pragnon, C., A. Janin, L. Michel, A. Thomaïdis, Y. Legrand, C. Soria, H. Lu. Urokinase localization and activity in isolated eosinophils. **88:**373
Madlener, K., see Pötzsch, B. **86:**373
Maeda, H., see Oida, K. **85:**169
Magsaam, J., see Beck, K.-H. **88:**337
Makogonenko, E.M., see Druzhyna, N.N. **87:**131
Makris, T.K., C. Tsoukala, P. Krespi, A. Hatzizacharias, A. Gialeraki, J. Papargyriou, V. Votteas, T. Mandalaki. Haemostasis balance disorders in patients with essential hypertension. **88:**99
Malkoç, S., see Haznedaroğlu, Ş. **86:**89
Mandalaki, T., see Makris, T.K. **88:**99
Manfredini, R., M. Gallerani, F. Portaluppi, R. Salmi, C. Fersini. Chronobiological patterns of onset of acute cerebrovascular diseases. **88:**451
Mannhalter, C., see Ruzicka, K. **87:**501
Mannucci, P.M., see Zighetti, M.L. **85:**279
Mari, D., see Parnetti, L. **87:**225
Marietta, M., F. Facchinetti, I. Neri, F. Piccinini, A. Volpe, G. Torelli. L-arginine infusion decreases platelet aggregation through an intraplatelet nitric oxide release. **88:**229
Markiewicz; W.T., see Lewandowski, K. **85:**105
Markland, F.S., see Sanchez, E.F. **87:**289
Marqués, A., see Zúñiga, A. **86:**243
Martín-Romero, M., see De La Cruz, J.P. **87:**141
Martínez, A.M., see Catalán, R.E. **87:**547
Martinez-Sales, V., see Vila, V. **86:**263
Martinka, E., see Galajda, P. **85:**63
Marutsuka, K., see Kisanuki, A. **85:**95
Masuyama, J.-I., see Funayama, H. **85:**377
Mathieu, B., see Raoul, M. **88:**441
Mathonnet, F., see Raoul, M. **88:**441
Matovic, M., see De Cicco, M. **86:**101
Matsuda, M., see Funayama, H. **85:**377
Matsumoto, A., see Iguchi, K. **85:**167
Matsumura, K., see Ikarugi, H. **85:**351
Matsuo, M., see Suzuki, S. **88:**499
Matsuo, T., see Imiya, M. **88:**245
———, see Suzuki, S. **88:**499
Matsuoka, A., see Yamashita, T. **85:**45
Matthews, I.T.W., see Head, D.M. **85:**327
Maximo, M.A., see De La Cruz, J.P. **86:**515
May, J.A., S. Heptinstall, A.T. Cole, C.J. Hawkey. Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300mg, plain aspirin 75mg and enteric coated aspirin 300mg, in man. **88:**183
Mazeaud, M.M., see Kuneš, J. **88:**347
McBride, E., see Dace, R. **87:**113
McCollum, C.N., see Blann, A.D. **85:**433
McFadden, E.P., see Agraou, B. **88:**237
McGuinness, C.L., see Humphries, J. **87:**123
McKeown, L.P., see Krutzsch, H. **88:**333
———, see Williams, S.B. **86:**417
McNerlan, S.E., V.L.S. Crawford, R.W. Stout. Measurement of fibrinogen in frozen plasma. **88:**481
Meinertz, T., see Gutensohn, K. **86:**49
Merhi, Y., see Provost, P. **85:**315
Merryman, P., A. Cullinane, M. Horne III. Comparison of two ELISAs for platelet factor 4 (Letter to the Editors-in-Chief). **86:**525
Meyers, W., see Gallistl, S. **88:**355
Mezzano, D., R. Tagle, E. Pais, O. Panes, M. Pérez, P. Downey, B. Muñoz, E. Aranda, P. Barja, S. Thambo, F. González, S. Mezzano, J. Pereira. Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure. **88:**465
Mezzano, S., see Mezzano, D. **88:**465
Michalec, L., see Walkowiak, B. **87:**95
Michel, L., see Mabilat-Pragnon, C. **88:**373
Micheli, S., see Rosati, D. **85:**273
Michitsch, A., see Novacek, G. **88:**283
———, see Ruzicka, K. **87:**431
Mielicka, E., see Mielicki, W.P. **87:**251
Mielicki, W.P., E. Mielicka, S.G. Gordon. Cancer procoagulant activity studies using synthetic peptidyl substrates. **87:**251
Milani, M., see Lorena, M. **87:**397
Mimuro, J., see Funayama, H. **85:**377
Mindroiu, T.M., see Carbini, L.A. **85:**33
Minix, R., V.M. Doctor. Interaction of fucoidan with proteases and inhibitors of coagulation and fibrinolysis. **87:**419
Miret, C., see Font, J. **86:**37
Mochida, S., see Yamanobe, F. **85:**493
Mokáň, M., see Galajda, P. **85:**63
Møller, J.M., G.L. Nielsen, S. Ekelund, E.B. Schmidt, J. Dyerberg. Homocysteine in Greenland Inuits. **86:**333
Monden, M., see Ariyoshi, H. **88:**427
———, see Kawasaki, T. **88:**67
———, see Nakamura, T. **85:**83
Montaño, L.F., see Collados, M.T. **85:**465
Montes, R., see Collados, M.T. **85:**465
Morassut, S., see De Cicco, M. **86:**101
Moreno, A., see De La Cruz, J.P. **86:**515
Morikawa, T., see Muramatsu, R. **86:**453
Moriki, T., see Kitaguchi, T. **87:**235
Morita, T., see Atoda, H. **87:**271
Moriya, N., see Kawamura, M. **86:**275
Moriyama, Y., see Nakamura, K. **86:**161
Mousa, S.A., see Kapil, R.P. **86:**221
———, see Tsao, P.W. **88:**137
Mueller, M.M., see Weigel, G. **87:**363
Müller-Berghaus, G., see Pötzsch, B. **86:**373
Muñoz, B., see Mezzano, D. **88:**465
Muñoz, F.J., see Font, J. **86:**37
Muntean, W., see Gallistl, S. **88:**355
Murakami, S., see Iguchi, K. **85:**167
Muramatsu, M., see Katada, J. **88:**27
Muramatsu, R., M. Sasaki, N. Watanabe, Y. Goto, T. Okayama, E. Nukui, T. Morikawa, H. Hayashi. Antithrombotic effects of NF-6505, a novel anion-binding exosite inhibitor. **86:**453
Murata, M., see Kitaguchi, T. **87:**235
Murray, D.K., see Liu, L. **85:**399
Musiał, J., J. Radwan, A. Szczeklik. Aspirin delays thrombin generation in vitro through interaction with platelet phospholipids (Letter to the Editors-in-Chief). **85:**367
Mutanen, M., see Freese, R. **85:**147
Muurling, S., see Lins, M. **86:**433

Nagai, N., see Urano, T. **88:**75
Nagel, E., see Lins, M. **86:**433
Nair, C.H., E.A. Shats. Compaction as a method to characterise fibrin network structure: kinetic studies and relationship to crosslinking. **88:**381
Nair, C.H., see Veldman, F.J. **86:**183

Nakahara, K., see Hashimoto, Y. **88:**51
Nakai, T., see Oida, K. **85:**169
Nakajima, K., see Shiba, M. **87:**511
Nakajima, S., see Ikarugi, H. **85:**351
Nakamura, K., H. Toyohira, H. Kariyazono, K. Yamada, Y. Moriyama, A. Taira. Relationship between changes in F1+2 and TAT levels and blood coagulation early after prosthetic valve replacement. **86:**161
Nakamura, T., H. Ariyoshi, J.-i. Kambayashi, M. Ikeda, N. Shinoki, T. Kawasaki, M. Monden. Signal transduction system in epinephrine stimulated platelets; comparison between epinephrine sensitive and insensitive platelets. **85:**83
Nakatsuka, M., see Ozawa, T. **85:**515
Naran, N.H., N. Chetty. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects. **88:**399
Neri, I., see Marietta, M. **88:**229
Ng, S.-K., see Lee, T.-K. **87:**215
Nguyen, P., see Hézard, N. **88:**59
Nielsen, G.L., see Møller, J.M. **86:**333
Niewiarowski, S., see Wierzbicka, I. **85:**115
Niiya, K., see Ozawa, T. **85:**515
Nilsson, Å., see Zhou, L. **85:**53
Nilsson, K., see Tenno, T. **88:**215
Nishikawa, T., see Urano, T. **88:**75
Norbis, F., T. Barbui, M. Galli. Diluted Russell's viper venom time and colloidal silica clotting time for the identification of the phospholipid-dependent inhibitors of coagulation. **85:**427
Nordfang, O., see Holst, J. **86:**343
———, see Østergaard, P.B. **87:**447
Nordøy, A., see Hansen, J.-B. **85:**413
Novacek, G., S. Kapiotis, B. Jilma, P. Quehenberger, A. Michitsch, O. Traindl, W. Speiser. Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin. **88:**283
Nováková, I.R.O., see Janssen, M.C.H. **86:**423
Nowak, G., see Petrovan, R.J. **88:**309
Nukui, E., see Muramatsu, R. **86:**453
Numano, F., see Sakita, S.-y. **87:**461
Nunes, G.C., see Viel, K. **88:**147

Öberg, F., see Tenno, T. **88:**215
Obladen, M., see Sonntag, J. **87:**339
Ødegaard, O.R., see Abdulkadir, J. **86:**431
O'Grady, J., H. Kritz, P. Schmid, C. Pirich, H. Sinzinger. Effect of isradipine on in-vivo platelet function. **86:**363
O'Grady, J., see Pirich, C. **88:**41
Oguogho, A., see Kritz, H. **87:**257
Ohno, A., see Yamanobe, F. **85:**493
Ohtani, A., see Vinogradsky, B. **85:**305
Oida, K., H. Maeda, M. Kohno, T. Nakai, S. Horie, H. Ishii. Effect of a protein phosphatase inhibitor, okadaic acid, on thrombomodulin expression in cultured human umbilical vein endothelial cells. **85:**169
Okahara, K., see Ariyoshi, H. **88:**427
Okayama, T., see Muramatsu, R. **86:**453
Okuyama, M., see Ariyoshi, H. **88:**427
Olding, L.B., see Barbieri, B. **86:**127
Ookubo, R., see Saito, T. **87:**527
Oosthuizen, W., see Veldman, F.J. **86:**183
Oostryck, R., see Adams, M.J. **87:**245
Ordinas, A., see Font, J. **86:**37
———, see Serra, A. **87:**405
Örning, L., R.W. Stephens, L.B. Petersen, M.J.A.G. Hamers, H. Stormorken, K.S. Sakariassen. A peptide sequence from the EGF-2 like domain of FVII inhibits TF-dependent FX activation. **86:**57
Ørsted, H., see Østergaard, P.B. **87:**447
Østergaard, P., see Holst, J. **86:**343
Østergaard, P.B., T.C. Beck, H. Ørsted, A. Svendsen, O. Nordfang, P.M. Sandset, J.-B. Hansen. An enzyme linked immunosorption assay for tissue factor pathway inhibitor. **87:**447
Østerud, B. A global view on the role of monocytes and platelets in atherogenesis. **85:**1
———, see Kvernmo, H. D. **87:**559
Ostrowska, H. Cathepsin A-like activity in thrombin-activated human platelets: substrate specificity, pH dependence, and inhibitory profile. **86:**393
Owensby, D.A., see Grimsley, P.G. **88:**485
Ozawa, T., K. Niiya, N. Inoue, N. Kawahara, M. Nakatsuka, K. Tada, T. Kudo, N. Sakuragawa. A novel 4 base pair deletion mutation inducing type I antithrombin deficiency. **85:**515
Özcan, T., see Haznedaroğlu, Ş. **86:**89
Özcebe, O.İ., see Özdemir, O. **86:**405
Özdemir, O., N.M. Sayınalp, İ. Haznedaroğlu, N. Arık, O.İ. Özcebe, S. Dündar. Mean platelet volume, platelet count and platelet dimensional width during hemodialysis. **86:**405

Pabinger, I., see Ruzicka, K. **87:**431
Pabinger-Fasching, I., see Ruzicka, K. **87:**501
Padovani, P.K., see Kapil, R.P. **86:**221
Pais, E., see Mezzano, D. **88:**465
Palatka, K., see Huszka, M. **86:**173
———, see Udvardy, M. **87:**75
Panarello, G., see De Cicco, M. **86:**101
Panes, O., see Mezzano, D. **88:**465
Panzer, S., see Watzke, H.H. **87:**521
Papadogiannakis, N., see Barbieri, B. **86:**127
Papargyriou, J., see Makris, T.K. **88:**99
Papini, N., see Petroni, A. **87:**315
Páramo, J.A., see Collados, M.T. **85:**465
Parborell, M.F., see Duboscq, C. **86:**505
Parisi, S., see Pulcinelli, F.M. **85:**207
Park, N.-Y., see Kim, S.-H. **87:**387
Park, S., see Kim, Y.W. **86:**181
Park, S.S., see Kim, Y.W. **86:**181
Parker, C.J., see Liu, L. **85:**399
Parnetti, L., D. Mari, G. Abate, R. Balestreri, D. Cucinotta, R. Coppola, A. Cherubini, P. Ferrari, U. Senin. Vascular dementia Italian sulodexide study (VA.D.I.S.S.) clinical and biological results. **87:**225
Peller, J.D., see Rao, G.H.R. **85:**23
Peltier, J.-Y., see Raoul, M. **88:**441
Pendurthi, U.R., K.D. Anderson, H.L. James. Characterization of a full-length cDNA for rabbit factor X. **85:**503
Peng, L., J.-Z. Li, H.-Z. Wu, M.-J. Wang. The activation of human platelets mediated by two monoclonal antibodies raised against CD9. **87:**65
Pennewitz, A., L. Finkelberg, S. Krause, W. Lösche. Platelets inhibit the activity of platelet-activating factor acetylhydrolase in monocyte-derived macrophages. **86:**427
Pereira, J., see Mezzano, D. **88:**465
Pérez. M., see Mezzano, D. **88:**465
Pérez-García, M., see Pèrez-Requejo, J.L. **85:**259
Pèrez-Requejo, J.L., O. Lucena-Solano, M. Pérez-García, M.T. Santarelli. Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (enoxaparin). **85:**259. Correction. **87:**269
Perolini, S., see Lorena, M. **87:**397
Pescador, R., see Fisher, J. **85:**445

Pesciotti, M., see Pulcinelli, F.M. **85:**207
Peters, J., see Luddington, R. **87:**577
Petersen, L.B., see Örning, L. **86:**57
Petitou, M., see Hoffmann, P. **86:**325
Petroni, A., M. Blasevich, N. Papini, M. Salami, A. Sala, C. Galli. Inhibition of leukocyte leukotriene B_4 production by an olive oil-derived phenol identified by mass-spectrometry. **87:**315
Petrovan, R.J., J.W.P. Govers-Riemslag, G. Nowak, H.C. Hemker, J. Rosing, G. Tans. Purification and characterization of multisquamase, the prothrombin activator present in Echis multisquamatus venom. **88:**309
Pettirossi, G., see Basili, S. **85:**165
Piana, A., see Leoncini, G. **86:**153
Piccinini, F., see Marietta, M. **88:**229
Pietrucha, T., see Golański, J. **85:**127
Pignatelli, P., see Pulcinelli, F.M. **85:**207
Pilegaard, H.K., see Hasenkam, J.M. **85:**77
Pinto, S., V. Bruni, D. Rosati, D. Prisco, M. Costanzo, B. Giusti, R. Abbate. Effects of estrogen replacement therapy on thrombin generation. **85:**185
Pinto, S., see Rosati, D. **85:**273
Pirich, C., Y. Efthimiou, J. O'Grady, H. Sinzinger. Hyperalphalipoproteinemia and prostaglandin I_2 stability. **88:**41
Pirich, C., see O'Grady, J. **86:**363
Písaříková, A., see Hladovec, J. **88:**361
Po, H.L., see Lee, T.-K. **87:**215
Polat, O., see Bounameaux, H. **86:**271
Poller, L., see Wright, D. **85:**455
Porta, R., see Fisher, J. **85:**445
Portaluppi, F., see Manfredini, R. **88:**451
Posán, E., see Udvardy, M. **87:**75
Potron, G., see Hézard, N. **88:**59
Pötzsch, B., S. Hund, K. Madlener, C. Unkrig, G. Müller-Berghaus. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. **86:**373
Prandoni, P., see Scarano, L. **86:**93
Preda, L., N. Erba, S. Figini, G.C. Carniti, E. Rossi. An improved test to identify aPC-resistant factor V-Leiden. **86:**461
Pretorius, G.H.J., see van Zyl, W.B. **88:**419
Prisco, D., see Chiarantini, E. **87:**539
———, see Pinto, S. **85:**185
———, see Rosati, D. **85:**273
Provost, P., Y. Merhi. Endogenous nitric oxide release modulates mural platelet thrombosis and neutrophil-endothelium interactions under low and high shear conditions. **85:**315
Pruvost, A., see Closse, C. **85:**159
Pulcinelli, F.M., P. Pignatelli, M. Pesciotti, S. Sebastiani, S. Parisi, P.P. Gazzaniga. Mechanism of the persisting TxA2 receptor antagonism by picotamide. **85:**207
Pulcinelli, F.M., see Basili, S. **85:**165

Quehenberger, P., see Novacek, G. **88:**283
———, see Ruzicka, K. **87:**431, 501
Quinn, K.A., see Grimsley, P.G. **88:**485
Quirk, S.M., see Henrikson, K.P. **87:**205
Quon, C.Y., see Kapil, R.P. **86:**221

Radwan, G.M.H., see El-Sabban, F. **88:**193
Radwan, J., see Musiał, J. **85:**367
Rand, J.H., see Zangari, M. **85:**177
Rao, A.K., see Yang, X. **88:**317
Rao, G.H.R., J.D. Peller, J.G. White. Influence of ionized calcium on thrombin-induced down-regulation of GPIb/IX receptors on human platelets. **85:**23
Raoul, M., F. Mathonnet, J.-Y. Peltier, C. Collet, C. Boucly, G. Van Amerongen, B. Mathieu, E. Jaouen, P. de Mazancourt. An improved method for the detection of the G20210A transition in the prothrombin gene. **88:**441
Rapaport, S.I., see Gable, P.S. **86:**79
Rauch, R., see Ries, M. **85:**341
Ray, A., L.G. Hegde, J.B. Gupta. Thrombin receptor: a novel target for antiplatelet drug development. **87:**37. Correction. **88:**255
Réganon, E., see Vila, V. **86:**263
Rejto, L., see Huszka, M. **86:**173
Renard, M., see Closse, C. **85:**159
Renshaw, M., see Austin, H. **86:**409
Restivo, A., see Henrikson, K.P. **87:**205
Reverter, J.C., see Font, J. **86:**37
———, see Serra, A. **87:**405
Ries, M., J. Klinge, R. Rauch. Age-related reference values for activation markers of the coagulation and fibrinolytic systems in children. **85:**341
Rivers, R.P.A., see Stephens, A.C. **85:**387
Robinson, A.J., see Kerr, J.S. **88:**127
———, see Zhang, Z.-Y. **88:**389
Robinson, C.S., see Kerr, J.S. **88:**127
Rocha, E., see Collados, M.T. **85:**465
Rodgers, G.M., see Grosset, A.B. **86:**349
———, see Liu, L. **85:**399
Rogatti, W., see Kritz, H. **87:**257
Rosati, D., S. Micheli, S. Pinto, S. Fedi, V. Bruni, S. Bucciantini, A.P. Cellai, A.A. Liotta, D. Prisco, F. Stefanelli, R. Abbate. Changes in lipidic and hemostatic parameters induced by tibolone treatment. **85:**273
Rosati, D., see Pinto, S. **85:**185
Rösen, P., see Berkels, R. **87:**51
Rösen, R., see Berkels, R. **87:**51
Rosing, J., see Petrovan, R.J. **88:**309
Rossi, E., see Preda, L. **86:**461
Rossi, L., see Scarano, L. **86:**93
Rożek, M., see Lewandowski, K. **85:**105
Ruzicka, K., S. Kapiotis, P. Quehenberger, S. Handler, S. Hornykewycz, A. Michitsch, K. Huber, D. Clemens, M. Susan, I. Pabinger, S. Eichinger, B. Jilma, W. Speiser. Evaluation of bedside prothrombin time and activated partial thromboplastin time measurement by coagulation analyzer *CoaguChek Plus*® in various clinical settings. **87:**431
Ruzicka, K., S. Kapiotis, P. Quehenberger, S. Handler, I. Pabinger-Fasching, C. Mannhalter, B. Jilma, W. Speiser. Evaluation of a new screening assay Pro® Global for identification of defects in the protein C/protein S anticoagulant pathway. **87:**501

Saito, T., R. Ookubo, M. Kuriyama, R. Sano, A. Ichinose. Lipoprotein(a) concentration and molecular weight of apolipoprotein(a) in patients with cerebrovascular disease and diabetes mellitus. **87:**527
Sakamoto, S., see Suzuki, S. **88:**499
Sakariassen, K.S., see Örning, L. **86:**57
———, see Stormorken, H. **88:**1
Sakata, Y., see Funayama, H. **85:**377
Sakita, S.-y., Y. Kishi, F. Numano. Acute vigorous exercise attenuates sensitivity of platelets to nitric oxide. **87:**461
Sakon, M., see Ariyoshi, H. **88:**427
———, see Kawasaki, T. **88:**67
Sakuragawa, N., see Hayashi, T. **87:**105
———, see Iguchi, K. **85:**167
———, see Ozawa, T. **85:**515
Sala, A., see Petroni, A. **87:**315

Salami, M., see Petroni, A. **87:**315
Salmi, R., see Manfredini, R. **88:**451
Samama, M.M., see Abdelouahed, M. **86:**255
———, see Walenga, J.M. **86:**1
Sanchez, E.F., L.R. Bush, S. Swenson, F.S. Markland. Chimeric fibrolase: covalent attachment of an RGD-like peptide to create a potentially more effective thrombolytic agent. **87:**289
Sánchez de la Cuesta, F., see De La Cruz, J.P. **86:**515, **87:**141
Sandset, P.M., see Østergaard, P.B. **87:**447
———, see Schjetlein, R. **85:**153
San Juan, A.G., see Guerrero, B.A.G. **87:**83, 171
Sano, R., see Saito, T. **87:**527
Sano-Martins, I.S., M.L. Santoro, S.C.B. Castro, H.W. Fan, J.L.C. Cardoso, R.D.G. Theakston. Platelet aggregation in patients bitten by the Brazilian snake *Bothrops jararaca*. **87:**183
Santarelli, M.T., see Farías, C.E. **88:**81
———, see Pèrez-Requejo, J.L. **85:**259
Santoro, M.L., see Sano-Martins, I.S. **87:**183
Santoro, S.A., see Despotis, G.J. **86:**205
Sardella, C., see Scarano, L. **86:**93
Sardella, L., see Colucci, M. **87:**441
Sasaki, H., see Hayashi, T. **87:**105
Sasaki, M., see Muramatsu, R. **86:**453
Sasaki, Y., see Kawano, M. **86:**115
Sato, H., see Hashimoto, Y. **88:**51
Savion, N., see Varon, D. **85:**283
Savoritto, S., see Zighetti, M.L. **85:**279
Sayınalp, N.M., see Özdemir, O. **86:**405
Scarano, L., E. Bernardi, P. Prandoni, C. Sardella, L. Rossi, P. Carraro, P. Simioni, A. Girolami. Accuracy of two newly described D-dimer tests in patients with suspected deep venous thrombosis. **86:**93
Scher, J., see Zangari, M. **85:**177
Schjetlein, R., G. Haugen, P.M. Sandset, F. Wisløff. Reduced C4b-binding protein in preeclampsia. **85:**153
Schmid, P., see O'Grady, J. **86:**363
Schmidt, E.B., see Møller, J.M. **86:**333
Schorer, A.E. Discordant effects on eicosanoids and fibrin degradation products in two murine models of antiphospholipid antibody. **85:**295
Schrör, K., see Bretschneider, E. **87:**493
Schüttrumpf, J., see Watzke, H.H. **87:**521
Scicli, A.G., see Carbini, L.A. **85:**33
Scott, N.A., see Viel, K. **88:**147
Sebastiani, S., see Pulcinelli, F.M. **85:**207
Seigneur, M., see Closse, C. **85:**159
Semeraro, N., see Colucci, M. **87:**441
Senin, U., see Parnetti, L. **87:**225
Serebruany, V.L., see Gurbel, P.A. **88:**343
Serra, A., J. Esteve, J.C. Reverter, M. Lozano, G. Escolar, A. Ordinas. Differential effect of a low-molecular-weight heparin (dalteparin) and unfractionated heparin on platelet interaction with the subendothelium under flow conditions. **87:**405
Seth, P., R. Kumari, M. Dikshit. Alterations in the free radical generation and nitric oxide release from rat peripheral polymorphonuclear leukocytes following thrombosis. **87:**279
Seyberth, H.W., see Beck, K.-H. **88:**337
Shapiro, F.B., see Umarova, B.A. **85:**267
Shats, E.A., see Nair, C.H. **88:**381
Sheffield, W.P., see Cunningham, M.A. **88:**171
Shen, M.-C., J.-S. Lin, W. Tsay. High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation in venous thrombophilic Chinese patients in Taiwan. **87:**377
Shenkman, B., see Varon, D. **85:**283
Sheu, J.-R., Y.-C. Kan, W.-C. Hung, W.-C. Ko, M.-H. Yen. Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets. **88:**259
Shiba, M., K. Tadokoro, K. Nakajima, T. Juji. Bradykinin generation in RC-MAP during storage at 4°C and leukocyte removal filtration. **87:**511
Shim, Y.-S., see Kim, Y.W. **86:**181
Shimada, K., see Funayama, H. **85:**377
Shimizu, A., see Iguchi, K. **85:**167
Shinoki, N., see Nakamura, T. **85:**83
Sidebotham, A., see Wright, D. **85:**455
Siebeck, M., M. Spannagl, J. Bichler, H. Hoffmann, C. Gippner-Steppert, M. Jochum. Delayed treatment with desulfato-hirudin prevents fibrin formation in lipopolysaccharide-induced shock. **88:**473
Siegbahn, A., see Tenno, T. **88:**215
Signorello, M.G., see Leoncini, G. **86:**153, **87:**483
Siguret, V., M. Alhenc-Gelas, M. Aiach, J.N. Fiessinger, P. Gaussem. Response to DDAVP stimulation in thirteen patients with Buerger's disease. **86:**85
Simioni, P., see Scarano, L. **86:**93
Simon, M., see Zieger, B. **87:**57
Simon, R., see Lins, M. **86:**433
Singer, E., see Farías, C.E. **88:**81
Sinha, U., see Lin, P.H. **88:**365
Sinzinger, H., see Kritz, H. **87:**257
———, see Leitinger, N. **86:**337
———, see O'Grady, J. **86:**363
———, see Pirich, C. **88:**41
Sio, R., see Heilmann, E.J. **87:**159
Skjønsberg, O.H., see Bach-Gansmo, E.T. **86:**141
Smirnova, I.V., see Citron, B.A. **87:**303
Smith, A., see Humphries, J. **87:**123
Söderstedt, A., see Barbieri, B. **86:**127
Sommerová, Z., see Hladovec, J. **88:**361
Sönmez, H., see Ulutin, T. **88:**329
Sonntag, J., K. Bethge, E. Strauss, J.W. Dudenhausen, M. Obladen. Contact system in healthy term newborns: reference values in cord blood. **87:**339
Soria, C., see Mabilat-Pragnon, C. **88:**373
Spannagl, M., see Siebeck, M. **88:**473
Speiser, W., see Novacek, G. **88:**283
———, see Ruzicka, K. **87:**431, 501
Spiro, T.E., see Grosset, A.B. **86:**349
Stain-Malmgren, R., see Barbieri, B. **86:**127
Steele, C., see Blann, A.D. **85:**433
Stefanelli, F., see Rosati, D. **85:**273
Steiner, B., see Carroll, R.C. **88:**109
Stephens, A.C., R.P.A. Rivers. Suppression of human monocyte tissue factor synthesis by antisense oligodeoxynucleotide. **85:**387
Stephens, R.W., see Örning, L. **86:**57
Stockklauser, K., see Berkels, R. **87:**51
Stormorken, H., K.S. Sakariassen. Hemostatic risk factors in arterial thrombosis and atherosclerosis: the thrombin-fibrin and platelet-VWF axis. **88:**1
Stormorken, H., see Örning, L. **86:**57
Stout, R.W., see McNerlan, S.E. **88:**481
Strand, Ø., see Bach-Gansmo, E.T. **86:**141
Strauss, E., see Sonntag, J. **87:**339
Strauss, H.W., see Bunting, R.W. **88:**503
Strukova, S.M., see Umarova, B.A. **85:**267
Suehisa, E., see Kawasaki, T. **88:**67
Süer, S., see Ulutin, T. **88:**329
Suk, K., see Kim, S.-H. **87:**331, 387

Sultuybek, G., see Ulutin, T. **88:**329
Sumiyoshi, A., see Kisanuki, A. **85:**95
Sun, L., see Yang, X. **88:**317
Sung, S.-M., see Lee, T.-K. **87:**215
Susan, M., see Ruzicka, K. **87:**431
Sutor, A.H., see Zieger, B. **87:**57
Suzuki, S., S. Sakamoto, M. Koide, M. Matsuo, K. Fujii, T. Matsuo. Effective anticoagulation by argatroban during coronary stent implantation in a patient with heparin-induced thrombocytopenia. **88:**499
Svendsen, A., see Østergaard, P.B. **87:**447
Swenson, S., see Sanchez, E.F. **87:**289
Szatkowski, E., see Jeske, W.P. **88:**271
Szczeklik, A., see Domagala, T.B. **87:**411
———, see Musiał, J. **85:**367

Tachikawa, K., K. Hasumi, A. Endo. Enhancement of plasminogen binding and fibrinolysis by chloropeptin I. **87:**571
Tada, K., see Ozawa, T. **85:**515
Tadokoro, K., see Shiba, M. **87:**511
Tagle, R., see Mezzano, D. **88:**465
Taira, A., see Nakamura, K. **86:**161
Taka, T., see Ikarugi, H. **85:**351
Takada, A., see Urano, T. **88:**75
Takada, Y., see Urano, T. **88:**75
Takahashi, M., see Funayama, H. **85:**377
Takano, K., see Yoshinari, M. **86:**443
Takiguchi, Y., see Katada, J. **88:**27
Tamarin, I., see Varon, D. **85:**283
Tans, G., see Petrovan, R.J. **88:**309
Teger-Nilsson, A.-C., R. Bylund, D. Gustafsson, E. Gyzander, U. Eriksson. *In vitro* effects of inogatran, a selective low molecular weight thrombin inhibitor. **85:**133
Tenno, T., J. Botling, F. Öberg, K. Nilsson, A. Siegbahn. Tissue factor expression in human monocytic cell lines. **88:**215
Terashita, Z.-i., see Kawamura, M. **86:**275
ter Hark, P.J.C., see Janssen, M.C.H. **86:**423
Testa, V., see De Cicco, M. **86:**101
Tetaz, T.J., see Ward, C.M. **86:**469
Thambo, S., see Mezzano, D. **88:**465
Theakston, R.D.G., see Sano-Martins, I.S. **87:**183
Thomaïdis, A., see Mabilat-Pragnon, C. **88:**373
Thomas, C.N., see Viel, K. **88:**147
Thomson, J.M., see Wright, D. **85:**455
Togo, M., see Hashimoto, Y. **88:**51
Toma, C.D., see Weigel, G. **87:**363
Tonelli, F., see Chiarantini, E. **87:**539
Tones, M.A., see Head, D.M. **85:**327
Torelli, G., see Marietta, M. **88:**229
Tornai, I., see Huszka, M. **86:**173
Toyohira, H., see Nakamura, K. **86:**161
Traindl, O., see Novacek, G. **88:**283
Tsao, P.W., M.S. Forsythe, S.A. Mousa. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin $\alpha_{IIb}\beta_3$ (GPIIb/IIIa) antagonists, c7E3 and DMP728. **88:**137
Tsay, W., see Shen, M.-C. **87:**377
Tsoukala, C., see Makris, T.K. **88:**99
Tsuji, N., see Kawamura, M. **86:**275
Tsuji, T., see Yamashita, T. **85:**45

Üçışık, N., see Ulutin, T. **88:**329
Udvardy, M., E. Posán, K. Palatka, I. Altorjay, J. Harsfalvi. Effect of L-arginine on *in vitro* plasmin-generation and fibrinogenolysis. **87:**75
Udvardy, M., see Huszka, M. **86:**173
Ueda, T., see Ikarugi, H. **85:**351
Ulutin, T., H. Sönmez, N. Üçışık, S. Süer, Ç. Bayram, E. Kökoğlu, G. Sultuybek. The molecular markers of hemostatic activation on coronary artery disease. **88:**329
Umarova, B.A., F.B. Shapiro, A.E. Kogan, S.M. Strukova. Mast cells secrete heparin during immobilization stress in rats. **85:**267
Unkrig, C., see Pötzsch, B. **86:**373
Uno, I., see Katada, J. **88:**27
Urano, T., T. Nishikawa, N. Nagai, Y. Takada, A. Takada. Amounts of tPA and PAI-1 in the euglobulin fraction obtained at different pH: their relation to the euglobulin clot lysis time. **88:**75

Vaage, J., see Winnerkvist, A. **85:**245
Valanzano, R., see Chiarantini, E. **87:**539
Valen, G., see Winnerkvist, A. **85:**245
Van Amerongen, G., see Raoul, M. **88:**441
Vandevender, D., see Fu, K. **86:**355
van Dinther, T.G., see Lormeau, J.C. **85:**67
van Zyl, W.B., G.H.J. Pretorius, M. Hartmann, H.F. Kotzé. Production of a recombinant antithrombotic and fibrinolytic protein, PLATSAK, in Escherichia coli. **88:**419
Varon, D., R. Dardik, B. Shenkman, S. Kotev-Emeth, N. Farzame, I. Tamarin, N. Savion. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. **85:**283
Veldman, F.J., C.H. Nair, H.H. Vorster, W.J.H. Vermaak, J.C. Jerling, W. Oosthuizen, C.S. Venter. Dietary pectin influences fibrin network structure in hypercholesterolaemic subjects. **86:**183
Venter, C.S., see Veldman, F.J. **86:**183
Verbruggen, B.W., see Janssen, M.C.H. **86:**423
Vermaak, W.J.H., see Veldman, F.J. **86:**183
Viel, K., J. Cui, C.N. Thomas, G.C. Nunes, S.B. King III, G.D. Cipolla, N.A. Scott. Inhibition of platelet deposition with local delivery of heparin using a double balloon catheter. **88:**147
Vieri, M., see Basili, S. **85:**165
Vila, V., V. Martinez-Sales, E. Réganon, J. Aznar. Fibrinopeptide A release from intraplatelet fibrinogen is related to thrombin platelet activation. **86:**263
Villalobos, M.A., see De La Cruz, J.P. **87:**141
Vinazzer, H. A new modification of the APC resistance test. **86:**69
Vinogradsky, B., S.P. Bell, J. Woodcock-Mitchell, A. Ohtani, S. Fujii. A new butadiene derivative, T-686, inhibits plasminogen activator inhibitor type-1 production in vitro by cultured human vascular endothelial cells and development of atherosclerotic lesions in vivo in rabbits. **85:**305
Violi, F., see Basili, S. **85:**165
Visser, A., see Lormeau, J.C. **85:**67
Volpe, A., see Marietta, M. **88:**229
Vorster, H.H., see Veldman, F.J. **86:**183
Votteas, V., see Makris, T.K. **88:**99

Wakisaka, M., see Yoshinari, M. **86:**443
Walenga, J.M., W.P. Jeske, L. Bara, M.M. Samama, J. Fareed. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. **86:**1
Walenga, J.M., see Hoppensteadt, D.A. **88:**159
———, see Jeske, W.P. **88:**271
———, see Kaiser, B. **87:**197
Walkowiak, B., A. Kęsy, L. Michalec. Microplate reader—a convenient tool in studies of blood coagulation. **87:**95
Wallén, N.H., M. Ladjevardi, J. Albert, A. Bröijersén. Influence

of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin. **87:**151
Wang, G., see Ledford, M.R. **87:**473
Wang, M.-J., see Peng, L. **87:**65
Wang, X.-f., see Carroll, R.C. **88:**109
Ward, C.M., T.J. Tetaz, R.K. Andrews, M.C. Berndt. Binding of the von Willebrand factor A1 domain to histone. **86:**469
Warpeha, R.L., see Fu, K. **86:**355
Watala, C., see Golański, J. **85:**127
Watanabe, N., see Muramatsu, R. **86:**453
Watanabe, S., see Kawano, M. **86:**115
Watanabe, T., see Hashimoto, Y. **88:**51
Watzke, H.H., J. Schüttrumpf, S. Graf, K. Huber, S. Panzer. Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. **87:**521
Weber, A.-A., see Bretschneider, E. **87:**493
Weigel, G., A. Griesmacher, C.D. Toma, C. Baecker, H. Heinzl, M.M. Mueller. Endothelial eicosanoid metabolism and signal transduction during exposure to oxygen radicals injury. **87:**363
Wetzels, I., see Wnendt, S. **85:**217
Wexler, R.S., see Kerr, J.S. **88:**127
———, see Zhang, Z.-Y. **88:**389
White, J.G., see Rao, G.H.R. **85:**23
Whitton, C., see Humphries, J. **87:**123
Wierzbicka, I., M.A. Kowalska, E.C. Lasz, D.H. Farrell, A.Z. Budzynski, S. Niewiarowski. Interaction of β_3 integrin-derived peptides 214-218 and 217-231 with $\alpha_{IIb}\beta_3$ complex and with fibrinogen Aα-chain. **85:**115
Wilkinson, R.A., see Bunting, R.W. **88:**503
Williams, S.B., H. Krutzsch, L.P. McKeown, H.R. Gralnick. Glycocalicin derived peptides inhibit von Willebrand factor binding to platelets. **86:**417
Williams, S.B., see Krutzsch, H. **88:**333
Wiman, B., see Winnerkvist, A. **85:**245
Winnerkvist, A., B. Wiman, G. Valen, J. Vaage. Oxidative stress and release of tissue plasminogen activator in isolated rat hearts. **85:**245
Wisløff, F., see Bach-Gansmo, E.T. **86:**141
———, see Jacobsen, E.M. **86:**385
———, see Schjetlein, R. **85:**153
Wittpoth, M., see Bretschneider, E. **87:**493
Wnendt, S., I. Wetzels, W.A. Günzler. Amyloid β peptides stimulate tissue-type plasminogen activator but not recombinant prourokinase. **85:**217
Wolf, H., see Fu, K. **86:**355
Woodcock-Mitchell, J., see Vinogradsky, B. **85:**305
Woods, A.I., see Farías, C.E. **88:**81
Wright, D., L. Poller, J.M. Thomson, G.E. Burrows, C.F. Hirst, A. Sidebotham. The effect of hormone replacement therapy on the age-related rise of factor VIIc, and its activity state. **85:**455
Wu, H.-Z., see Peng, L. **87:**65

Xu, N., see Zhou, L. **85:**53

Yakovlev, S.A., see Druzhyna, N.N. **87:**131
Yamada, K., see Nakamura, K. **86:**161
Yamada, M., see Atoda, H. **87:**271
Yamamoto, J., see Ikarugi, H. **85:**351
———, see Kawano, M. **86:**115
———, see Yamashita, T. **85:**45
Yamamoto, M., see Yoshinari, M. **86:**443
Yamanobe, F., S. Mochida, A. Ohno, K. Ishikawa, K. Fujiwara. Recombinant human tissue factor pathway inhibitor as a possible anticoagulant targeting hepatic sinusoidal walls. **85:**493
Yamashita, M. Bactericidal/permeability-increasing protein ameliorates hypercoagulability after hemorrhagic shock. **87:**323
Yamashita, M., M. Yamashita. Tumor necrosis factor alpha is involved in the induction of plasminogen activator inhibitor-1 by endotoxin. **87:**165
Yamashita, T., T. Tsuji, A. Matsuoka, J.C. Giddings, J. Yamamoto. The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. **85:**45
Yan, S.-H., see Lee, T.-K. **87:**215
Yang, L.H., J. Fareed. Vasomodulatory action of clopidogrel and ticlopidine. **86:**479
Yang, L.H., see Hoppensteadt, D.A. **88:**159
Yang, X., L. Sun, J. Gabbeta, A.K. Rao. Platelet activation with combination of ionophore A23187 and a direct protein kinase C activator induces normal secretion in patients with impaired receptor mediated secretion and abnormal signal transduction. **88:**317
Yen, M.-H., see Sheu, J.-R. **88:**259
Yoon, K.-Y., see Kim, Y.W. **86:**181
Yoshihara, E., see Atoda, H. **87:**271
Yoshinari, M., M. Yamamoto, M. Wakisaka, M. Iwase, K. Takano, M. Fujishima. Effect of bezafibrate on hypercoagulability assessed by fluorogenic prothrombin time in hyperlipidemic patients with non-insulin-dependent diabetes mellitus. **86:**443
Yuan, R.-Y., see Lee, T.-K. **87:**215

Zangari, M., C.J. Lockwood, J. Scher, J.H. Rand. Prothrombin activation fragment (F1.2) is increased in pregnant patients with antiphospholipid antibodies. **85:**177
Zawilska, K., see Lewandowski, K. **85:**105
Zhang, Z.-Y., J. Kerr, R.S. Wexler, H.-y. Li, A.J. Robinson, P.P. Harlow, L.S. Kaminsky. Warfarin analog inhibition of human CYP2C9-catalyzed S-warfarin 7-hydroxylation. **88:**389
Zhou, L., N. Xu, Å. Nilsson. Intralipid rapidly attenuates the agonist-induced activation of rat platelets *in vitro*. **85:**53
Zicha, J., see Kuneš, J. **88:**347
Zieger, B., U. Budde, U. Jessat, R. Zimmermann, M. Simon, R. Kätzel, A.H. Sutor. New families with von Willebrand disease type 2M (Vicenza). **87:**57
Zighetti, M.L., M. Cattaneo, C.R. Falcon, R. Lombardi, S. Harari, S. Savoritto, P.M. Mannucci. Absence of hyperhomocysteinemia in ten patients with primary pulmonary hypertension. **85:**279
Zimmermann, R., see Zieger, B. **87:**57
Zöller, B., A. Hillarp, B. Dahlbäck. Activated protein C resistance caused by a common factor V mutation has a single origin. **85:**237
Zoubine, M.N., see Citron, B.A. **87:**303
Zúñiga, A., A. Marqués, M. Gabaldón. Proinflammatory activity on rat carotid endothelium of albumins obtained by different procedures. **86:**243
Zurborn, K.-H., see Dürig, J. **85:**479
———, see Lins, M. **86:**433

Pergamon

Thrombosis Research 88 (1997) 541–545

THROMBOSIS RESEARCH

Keyword Index—Volumes 85–88 (1997)

abciximab **88:**271
acetylsalicylic acid **86:**127
activated factor VII **86:**493
activated protein C **87:**197, 577
activated protein C resistance **86:**431; **88:**409
activation markers **85:**341
acute aerobic exercise **85:**351
acute myocardial infarction **85:**217; **88:**343
acyl enzyme **88:**365
adhesion **86:**287
adhesion molecules **85:**433
ADP **88:**347
adverse transfusion reaction **87:**511
aerobic conditioning **87:**559
aggregation **85:**33; **85:**345; **86:**287; **87:**95; **88:**183
aggregometer **87:**95
albumin **86:**243
alteplase **85:**245
amidolytic activity **87:**251
amyloid β peptides **85:**217
analysis **87:**447
angioplasty **88:**237
animal models **85:**295
antibodies to protein S **86:**197
anticardiolipin antibodies **85:**295; **86:**37
anticoagulant **85:**133; **86:**57; **87:**113
anticoagulant function **85:**413
anticoagulant protein **87:**271
anticoagulant therapy **86:**161
anticoagulation **87:**441
anti-factor Xa **85:**67
anti-peptide antibodies **87:**205
antiphospholipid antibodies **85:**295, 427, 439; **86:**37, 385; **87:**539; **88:**355
antiphospholipid syndrome **85:**177; **86:**37
antiplatelet **88:**419
antiplatelet activity **87:**483
antiplatelet agent **86:**221
antiplatelet drugs **85:**207
antiplatelet peptide **87:**289
antisense oligodeoxynucleotide **85:**387
antithrombin **85:**225, 515; **86:**1; **87:**577; **88:**171, 419
antithrombin activity **87:**105
antithrombin-III **85:**67
antithromboplastin antibodies **86:**37
antithrombotic **86:**1; **88:**159
anti-Xa **85:**259
APC resistance **85:**237, 357; **86:**69; 385, 461; **87:**263
APCR **88:**59
apolipoprotein A **88:**41
apolipoprotein(a) **87:**527
APSAC **86:**255
aPTT **88:**355
arachidonic acid **85:**83; **87:**279
argatroban **86:**115, **88:**245, 499
Artemisia princeps **87:**105
arterial **88:**1
arterial thrombosis model **86:**275
ASA PCR **88:**59
asialo von Willebrand factor **86:**417
aspirin **85:**367; **87:**151, 215; **88:**183, 193
aspirin/dipyridamole **87:**359
AT-III **87:**113, 419
atherogenesis **85:**1
atherosclerosis **85:**305, **86:**363, 427; **87:**141, 411, 527; **88:**1, 99
auto-antibodies **86:**73

baculovirus expression **87:**205
Behcet's disease **86:**197
beta-thromboglobulin **86:**173
bezafibrate **86:**443
biodistribution **88:**503
biological half-life **88:**41
biological matrix **86:**221
bleeding time **86:**275
blood cells **85:**1
blood clotting **85:**185
blood coagulation **88:**215, 283
blood platelets **85:**367
bovine serum **85:**439
bradykinin **87:**511
Buerger's disease **86:**85

CAD **88:**329
calcium **85:**23; **85:**327
calcium mobilization **88:**317
cAMP **87:**483; **88:**89, 399
cAMP phosphodiesterase **87:**483
cancer patient **86:**101
cancer procoagulant **87:**251
cardiac surgery **86:**205
carotid **86:**243
casein kinase II **87:**331
catecholamines **85:**267
cathepsin A **86:**393
C4b-binding protein **85:**153
CD14 **85:**387
CD62 (P-selectin) **87:**473
cDNA **85:**503
cell–cell-interaction **86:**427
central venous catheter **86:**101
cerebral **88:**193
cerebral infarction **88:**245
children **85:**341; **88:**355
chimeric enzyme **87:**289
Chinese **87:**215
Chinese population **88:**409
cholecystectomy **86:**271
cholesterol **85:**53; **88:**347
cholesterol-fed **87:**123
chromogenic substrates **87:**251
C1-inhibitor **87:**339
circadian rhythm **88:**451
circannual rhythm **88:**451
circaseptan rhythm **88:**451
citrate **87:**151
clauss **88:**481
clearance **85:**23
clinical evaluation **87:**431
clinical trials **87:**215
clopidogrel **86:**479
clot lysis **87:**75
clot strength **85:**519
clotting activation **86:**433
clotting assay **86:**461
CoaguChek® **85:**77
CoaguChek Plus® **87:**431
coagulation **85:**147, 195, 273, 341; **86:**205; **87:**83, 171, 539; **88:**1
coagulation factor IX-binding protein **87:**271
coagulation factors **86:**233
compaction **88:**381
complex D-D-N-DSK of fibrin **87:**131
complex fibrinogen-N-DSK of fibrin **87:**131
coronary angioplasty **88:**499
coronary artery disease **88:**41
coronary heart disease **87:**521
Coumadin® **88:**127
Crohn's disease **87:**539
crosslinking **88:**381
C-terminal hirudin peptides **86:**453
C-type lectin-like domain **87:**271
cyclic AMP **86:**337

0049-3848/97 $17.00 + .00 © 1998 Elsevier Science Ltd. Printed in the USA. All rights reserved.
PII S0049-3848(98)00068-1

cyclic GMP **87:**461, 547
cyclooxygenase inhibitor **88:**51
CYP2C9 **88:**389
cytokine **87:**323
cytokines **88:**215
cytotoxicity **85:**345

dalteparin **87:**405
danazol **87:**473
DAPTTIN **86:**69
DDAVP **86:**85
D-dimer **86:**89, 93, 141, 161, 423; **88:**291, 413
deep vein thrombosis **86:**271; **88:**67, 413
deep venous thrombosis **86:**93, 423; **88:**291
deficiencies **86:**73
deficiency **85:**515
degradation **87:**171
deletion **85:**515
β_3-derived peptides **85:**115
dermatan sulfate **87:**441
desulfato-hirudin **88:**473
development **87:**303
diabetes **87:**257
diabetes mellitus **85:**63
diabetic angiopathy **86:**173
DIC **87:**323
dietary fibre **86:**183
dipeptide **85:**133
directional coronary atherectomy **86:**433
divalent metal ions **85:**327
down-regulation **85:**23
drug development **87:**37
dysprothrombinemia **85:**465; **88:**337

EACA **87:**359
ecarin clotting time **86:**373
Echis carinatus **88:**309
Echis carinatus venom **85:**369
Echis multisquamatus **88:**309
ECLT **88:**75
EDRF-NO **86:**173
EDTA-dependent thrombocytopenia **85:**127
EGF-like domain **86:**57
EGTA **85:**127
eicosanoids **85:**295; **87:**363
elastase **86:**141; **88:**171
ELISA **85:**439; **86:**525; **88:**343
ELISA test **86:**141
ellagic acid **87:**359
3′-end penultimate position mismatched primers **85:**105
endocytosis **85:**387
endothelial cell markers **88:**465
endothelial cells **85:**305, 377, 433; **87:**363
endothelial dysfunction **87:**323
endothelial lesion **88:**361
endothelin-1 **86:**479
endothelium **85:**159, 245, 399; **88:**99
endotoxin **85:**295; **87:**165
enoxaparin **85:**259; **86:**349
enoximone **88:**89
enteric coating **88:**183
enzymatic characteristics **86:**393
enzyme kinetics **87:**343
enzyme linked immunosorption assay **87:**447
eosinophils **88:**373
epinephrine **85:**83
erythrocytes **86:**515
essential hypertension **88:**99
estrogen **85:**1
estrogen replacement therapy **85:**185
Ethiopian **86:**431
etiology **88:**67
evaluation in thrombophilia patients **87:**501
exercise **87:**461
exosite-1 **86:**301
expanded polytetrafluoroethylene grafts **88:**427
experimental thrombosis **87:**353
expression **88:**485

F1.2 **85:**177
F1+2 formation **87:**197
factor V **85:**237; **86:**79, 181, 431
factor V Leiden **85:**357; **86:**409, 461; **88:**59, 441
factor V mutation **87:**377
factor VII **85:**327; **86:**57; **88:**445
factor VII amidolytic activity **86:**493
factor VII clotting activity **86:**493
factor VIIa **85:**225, 455; **86:**423
factor VIIag **85:**455
factor VIIc **85:**455
factor VIII **86:**79
factor X **85:**503
factor Xa **85:**45; **86:**1; **88:**365
factor XIII **87:**83, 171
FcγRIIa1 **86:**255
FcγRIIa2 **86:**255
fibrates **87:**1
fibrin **87:**1
fibrin crosslinking **87:**83
fibrin degradation products **85:**295; **88:**413
fibrin network structure **86:**183; **88:**381
fibrin polymerization **86:**301
fibrinogen **85:**115, 519; ;386:183; **87:**1, 225, 331; **88:**27, 81, 481
fibrinogen receptor antagonists **88:**109
fibrinogen variants **85:**115
fibrinogenolysis **87:**75
fibrinolysis **85:**147, 185, 195, 273, 295, 305, 341; **86:**85, 433, 505; **87:**75, 387, 539, 571; **88:**75, 283
fibrinolytic potential **87:**559
fibrinolytical activity **85:**363
fibrinopeptide A **85:**185; **86:**263
filtration **87:**511
flow cytometry **85:**479; **86:**49; **87:**197
flowing systems **87:**405
fluvastatin **87:**397
free radicals **85:**245; **88:**435

fructose **86:**515
fucoidan **85:**479; **87:**419

garlic **88:**193
genes **87:**235
genetic hypertension **88:**347
genetic polymorphism **87:**521
Glu-plasminogen **87:**131
Glu-plasminogen activation **87:**131
glycocalicin **86:**417
glycoprotein Ibβ **87:**235
glycoprotein Ib/IX **85:**23
glycoprotein IIb/IIIa **88:**27
glycoprotein IIb/IIIa complex **88:**259
glycosaminoglycan binding domain **87:**105
GMP-140 **85:**127
GP IIb/IIIa **88:**271
GP IIb/IIIa receptor antagonist **86:**221
GPIIb/IIIa antagonist **86:**275
G-protein **88:**205
granulocytes **88:**373

haemorrhagic stroke **85:**217
haemostasis **88:**41, 99
haemostasis factors **87:**225
Hageman factor **87:**339
haplotype **85:**237
HC-II **87:**113
HDL-cholesterol **88:**41
hemodialysis **86:**405; **88:**159, 283
hemophilia **88:**365
hemorrhage **87:**323
hemostasis **86:**89, 363; **87:**331
hemostatic activation **88:**329
hemostatic defect **88:**465
He-Ne laser **85:**45
hep G2 cells **88:**485
heparan sulfate **88:**299
heparin **85:**259, 267; **86:**1, 317, 325, 349, 355; **87:**359; **88:**147, 159, 271, 283, 503
heparin cofactor II **87:**105
heparin-binding exosite-2 **86:**301
heparin-induced thrombocytopenia **88:**499
hepatocyte **85:**493
hirudin **86:**453; **87:**151, 343
histone **86:**469
homocysteine **85:**279; **86:**333; **87:**411
homocysteinemia **88:**361
hormonal replacement therapy **85:**273
HPLC **86:**127
HRT **85:**455
human **85:**147
human neutrophil elastase **86:**505
human platelet aggregation **88:**109
hydrogen peroxide **85:**245; **86:**153
hydroxytyrosol **87:**315
hyperalphalipoproteinemia **88:**41
hypercholesterolaemia **86:**183; **88:**399
hypercholesterolemia **87:**397; **88:**67
hypercoagulability **86:**443; **87:**353
hypercoagulable **87:**359

hypercoagulation **85:**237
hyperhomocysteinaemia **88:**441
hyperhomocysteinemia **85:**279
hyperlipidemia **86:**443
hypertension **86:**363
hypotension **87:**511
hypoxia **85:**159
hypoxia-reoxygenation **85:**159

IgG anti-streptokinase **86:**255
IL-6 **87:**1
immunoassay **86:**525; **88:**343
immunological platelet activation **86:**255
impedance aggregometry **87:**151
in vitro **86:**49
inflammation **87:**1
inherited thrombocytopathy **88:**317
inhibitor protein deficiencies **87:**377
injury **85:**245
inogatran **85:**133
insensitivity **85:**83
$\alpha_v\beta_3$ integrin **88:**137
integrin $\alpha_{IIb}\beta_3$ (GPIIb/IIIa) **85:**115, 127; **88:**137
international normalized ratio (INR) **85:**77
intracellular calcium **88:**259
intracoronary stents **86:**49
intrinsic pathway **86:**73
Inuits **86:**333
invertebrate venoms **87:**171
in-vivo **86:**363
iodination **87:**343
[^{125}I]-oligotide **85:**445
ischemic **87:**215
isoelectric precipitation **88:**75
isoprostanes **86:**337
isradipine **86:**363

kinetic constants **87:**251
kininogen **87:**339
knee arthroplasty **85:**195
Korean **86:**181
kringle domain **87:**527

laparoscopic surgery **86:**271
L-arginine **87:**75; **88:**229
L-Arginine infusion **88:**229
latex agglutination test **86:**141
L-Citrulline **88:**229
LDL **85:**413
Leiden mutation **85:**105; **87:**263
leukocyte **85:**315
leukocyte adhesion **86:**243
leukotriene B_4 **87:**315
linkage disequilibrium **88:**445
lipid peroxidation **86:**173; **87:**411
lipids **85:**1; 273
lipopolysaccharide **85:**295
lipopolysaccharide shock **88:**473
lipoprotein(a) **87:**527
lipoproteins **85:**53
liposome **85:**53
LMWH **86:**343, 355
L-NAME **85:**315
local delivery **88:**147
Lonomia achelous **87:**83, 171
low dose **88:**183
low molecular mass heparin **87:**151
low molecular weight heparin **86:**325
low-back pain **85:**363
low-molecular-weight heparin **85:**259; **86:**271, 349; **87:**405
LRP **88:**485
lucigenin dependent chemiluminescence **87:**279
luminol dependent chemiluminescence **87:**279
lupus **85:**295
lupus anticoagulant **85:**295, 427; **86:**37, 73, 385; **87:**245, 577; **88:**355

macrophages **86:**427
magnesium **85:**127
mast cells **85:**267
mean platelet volume **86:**405
meizothrombin **85:**369
meizothrombin-(des F1) **85:**369
metalloprotease **87:**289
methionine load **88:**361
methionine loading test **87:**411
mice **85:**295
microcirculation **88:**193
microplate reader **87:**95
migration **86:**317
mini-plasminogen **86:**505
mitogenesis **87:**493
molecular markers **88:**329
molecular weight dependence **85:**479
monitoring coagulation **86:**205
monkeys **88:**81
monoclonal antibody **87:**65
monocytes **85:**1, 377, 387; **86:**427; **88:**215, 237
mouse **87:**235; **88:**193
MTHFR **88:**441
MTHFR gene **86:**409
multiple organ failure **88:**473
muscle **87:**303
mutation **85:**237; **86:**181, 431
myocardial infarction **87:**397

n-3 fatty acids **85:**147
n-3 PUFA **86:**333
near patient testing **85:**77
neonate **87:**339
neurotransmitters **88:**435
NF-6505 **86:**453
NIDDM **86:**443
nitric oxide **87:**51; **87:**461
nitric oxide pathway **88:**229
nitrite **87:**279
non insulin dependent diabetes mellitus (NIDDM) **86:**153

okadaic acid **85:**169
oligotide's bioavailability **85:**445
oligotide's pharmacokinetics **85:**445
olive oil **87:**315
oral administration **85:**445
oral anticoagulant therapy **85:**77
Org 31540 **85:**67
origin **85:**439
orthotopic liver transplantation **85:**493
oxygen radicals **87:**363

PAF acetylhydrolase **86:**427
PAI-1 **86:**85; **87:**165, 419; **88:**75
p-aminobenzoic acid **86:**127
PCA-4230 **87:**547
PCR **88:**441
PDE inhibitor **88:**89
pectin **86:**183
pentasaccharide **85:**67; **86:**1; **88:**159
pentosan polysulphate **86:**325
pentoxifylline **87:**225
peptides **86:**57, 417; **88:**333
PF 1.2 **86:**89
pharmacodynamics **86:**221
pharmacokinetics **86:**221; **88:**503
phenolic antioxidants **87:**315
phlebography **86:**93
phosphatidylethanolamine **85:**439
phosphodiesterase **87:**547
phospholipase A_2 **85:**83
phospholipase A2 **88:**205
phospholipid **85:**399
phospholipid metabolites **88:**109
phospholipid-dependent clotting assays **85:**427
phosphorylated polysaccharides **87:**113
phosphorylation **87:**65
physical exercise **87:**559
pial **88:**193
picotamide **85:**207
pig **88:**473
piroximone **88:**89
plasma clotting **87:**95
plasma lipase activity **86:**325
plasminogen **87:**571
plasminogen activator inhibitor **85:**305
plasminogen activator inhibitor-1 **85:**377
plasminogen activators **88:**485
platelet **85:**45, 83, 315; **86:**263; **87:**461; **88:**27, 205
platelet activation **85:**53, 207, 479; **87:**65, 197; **88:**317
platelet adhesion **85:**283; **87:**405
platelet aggregation **85:**283, 351; **86:**337; **87:**141, 151, 183; **88:**89, 205, 229, 245, 259, 347
platelet antagonist **87:**37
platelet count **86:**205
platelet counting **87:**95
platelet deposition **88:**147
platelet factor 4 **86:**525
platelet function **85:**147, 185; **86:**363; **87:**159, 257, 405; **88:**399
platelet function disorders **88:**317
platelet function tests **87:**183
platelet glycoproteins **87:**65

platelet indices **86:**405
platelet NO release **87:**51
platelet NO synthases **87:**51
platelet poor plasma **86:**221
platelet procoagulant function **86:**205
platelet release reaction **85:**127
platelet response **87:**257
platelet rich plasma **86:**221
platelet secretion **88:**137
platelets **85:**1, 23, 33, 115, 345, 519; **86:** 49, 127, 153, 287, 417, 427, 515; **87:**51, 95, 235, 547; **88:**1, 183, 271, 333
platinum wire **87:**353
polyethylene glycol recombinant hirudin **87:**123
polymorphisms **88:**445
polymorphonuclear leukocytes **87:**315
polysaccharide **87:**105
postprandial **85:**147
preanalytical variables **86:**493
preeclampsia **85:**153
pregnancy **85:**177
prekallikrein **87:**339
preterm labor **86:**89
prevalence **88:**409
primary hemostasis **85:**283
primary pulmonary hypertension **85:**279
probenecid **85:**345
ProC® Global assay **87:**501
procoagulant potential **87:**559
proliferation **86:**317
prophylaxis **86:**271
prostacyclin **85:**295; **86:**515; **88:**283
prostaglandin E_1 **87:**257
prostaglandin I_2 **88:**41
prosthetic valve replacement **86:**161
Protac **86:**79
Protac C **86:**69
protamine **86:**343
protease-activated receptor **85:**33
protein binding **88:**127
protein C **85:**153; **87:**577
protein interactive sites **85:**503
protein kinase C **88:**317
protein kinase C inhibitor **88:**51
protein kinase C-independent exocytosis **88:**51
protein phosphatases **85:**169
protein S **85:**153; **86:**197; **87:**577
protein S deficiency **87:**473
protein tyrosine kinases **86:**287
proteoglycan **85:**493; **88:**299
prothrombin **85:**369; **86:**73; **87:**303, 521; **88:**441
prothrombin activation **85:**465; **88:**309, 337
prothrombin complex concentrates **86:**493
prothrombin deficiency **88:**337
prothrombin fragment 1+2 **86:**161
prothrombin fragment 1.2 (F1.2) **87:**473
prothrombinase complex **85:**465
prothrombotic state **85:**351
P-selectin **85:**159; **88:**137, 343
psychological traits **85:**363
pulmonary embolism **87:**441; **88:**291, 413
pulmonary thromboembolism **85:**95
pyrimidoquinoline and isoquinoline derivatives **87:**483

qRT-PCR **87:**303

rabbit **85:**503; **87:**123
rabbit model **85:**95
rabbits **85:**305
radiation damage **88:**81
rats **87:**353, 441; **88:**347
RC-MAP **87:**511
reactive oxygen intermediates **85:**245
recombinant **88:**419
recombinant tissue-type plasminogen activator **85:**519; **87:**123
reference ranges **86:**493
reproducibility **87:**353
restenosis **86:**433
RGD **88:**27
r-hirudin **86:**373
ridogrel **88:**399
Ro-31-7549 **88:**51

S. aureus **87:**387
secretion **88:**183
selectivity **85:**133
sepsis **86:**141
sequencing **87:**263
serotonin **86:**263, 479
serpins **88:**171
SEV **85:**33
shear **85:**283
shear rate **85:**315
shear-induced thrombosis **85:**351
signal transduction **87:**363
signal transduction defects **88:**317
silica clotting time **85:**427
sinusoidal endothelial cell **85:**493
smoking **85:**433
smooth muscle cells **86:**317; **87:**493
snake bites **87:**183
snake venom **87:**183, 271, 289; **88:**309
sodium citrate **87:**159
soluble fibrin **88:**291
soluble thrombomodulin **86:**173
sonicated red blood cell ghosts **85:**95
sorbitol **86:**515
sphingosine **87:**331
splenic artery ligation **85:**95
SR 90107A **85:**67
SR 90107A/Org 31540 **86:**325
staphylokinase **86:**115; **87:**387; **88:**419
stress **85:**267
stroke **87:**215; **88:**451
stroke prevention **87:**215
subcutaneous **87:**123; **88:**503
subendothelium **85:**283
sulfated polysaccharides **87:**113
sulodexide **87:**225
supranormal multimers **87:**57
surface plasmon resonance **85:**225
systemic anticoagulation **86:**373
systemic lupus erythematosus **86:**37

TAK-029 **86:**275
TFPI **85:**413; **86:**343
α-thrombin **88:**333
thrombin **85:**33, 133, 267; **86:**453; **87:**37, 343, 419, 493; **88:**171, 299, 347
thrombin adsorption **86:**301
thrombin catalytic site **86:**301
thrombin generation **85:**367
thrombin inhibitor **85:**133
thrombin receptor **87:**37, 205
thrombin receptor activating peptide **87:**205, 493
thrombin-antithrombin (TAT) **87:**473
thrombin-antithrombin III **86:**161
thrombin-antithrombin III complex **86:**89; **88:**427
thrombin-inhibitor design **86:**301
thrombin-stimulated human platelets **86:**393
thrombocytopenia **88:**271
thromboelastography **85:**519
β-thromboglobulin **88:**137
thrombolysis **85:**217, 351, 519; **86:**115, 233; **87:**289, 441
thrombomodulin **85:**63, 169
thrombophilia **86:**461; **88:**441
thrombophilia screening **87:**577
thrombosis **85:**45, 237, 279, 295, 515; **86:** 49, 101, 115, 349; **87:**1, 279, 527; **88:**1, 27, 99, 193, 435, 441
thrombosis activation **87:**353
thrombotic prophylaxis **85:**259
thromboxane **85:**295; **86:**127, 479; **87:**141; **88:**399
thromboxane A_2 **88:**259, 347
thromboxane B_2 **86:**263
thromboxane B2 **88:**205
ticlopidine **86:**479
tissue factor **85:**225, 327, 387, 399; **86:**57; **87:**245; **88:**215, 237
tissue factor pathway inhibitor **85:**63, 493; **87:**245, 397, 447
tissue-type plasminogen activator **85:**377
TMPZ **88:**259
topical anticoagulants **86:**355
tPA **88:**75
t-PA **86:**85, 317; **87:**131, 419; **88:**81
tranexamic acid **85:**195
transcription factors **85:**1
triglycerides **88:**347
Trimeresurus flavoviridis **87:**271
tumor necrosis factor **87:**165
TxA2 receptor **85:**207
type 1 plasminogen activator inhibitor **88:**137
type 2M (Vicenza) **87:**57

U937 cell **87:**571
UH **86:**343

unfractionated heparin **87:**405
unsaturated fatty acid **87:**141
u-PA **86:**317
uremia **88:**465
urokinase **87:**419
urokinase-type plasminogen activator **88:**373

vascular dementia **87:**225
vascular endothelial cell **88:**299
vascular trauma model **86:**355
vasomodulation **86:**479
venography **86:**271
venom **87:**83
venous thrombcembolism **88:**291
venous thrombophilia **87:**377
venous thrombosis **85:**259; **86:**181, 409; 453
vessel wall **85:**315
Vipera lebetina fibrinogenase **86:**233
vitamin K epoxide reductase **88:**127
von Willebrand disease **87:**57
von Willebrand factor **85:**63; **86:**173, 417, 469; **88:**81
von Willebrand factor binding **86:**417
vWF **86:**85; **88:**1

warfarin **88:**127, **88:**389
warfarin-drug interactions **88:**389
Western blotting **85:**413
white blood cell counts **86:**205
whole blood **88:**183
whole blood PCR **88:**59

XU063 **86:**221